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ABSTRACT 
 
HIV-associated cardiomyopathy is a multifactorial disease with a broad spectrum of 
aetiologies that arise due to chronic immunosupression during HIV infection. The intricate 
relationship between HIV infection and cardiac co-morbidity was investigated with the aid of 
HIV-neutralizing aptamers. These synthetic nucleic acid ligands with antibody-like properties 
are molecular tools with multifunctional applications ranging from drug discovery to 
diagnostics and therapeutics. The advent of the HIV/AIDS pandemic has naturally married 
the field of HIV therapy and diagnostics with that of aptamer technology. By employing a 
HIV-1 neutralizing aptamer, named UCLA1, raised against the viral surface envelope 
glycoprotein 120, I dissected some of the pathways leading to cardiomyocyte apoptosis in a 
cell culture system. In chapter one I investigated the potential cytotoxic effects of UCLA1 by 
comparing it against a panel of 17 antiretrovirals (ARVs) in clinical use with the goal of 
establishing a safety portfolio geared towards its use as a therapeutic agent. Using cultured 
human cardiomyocytes and primary peripheral blood mononuclear cells (PBMCs), I selected 
some of the major biological markers of ARV-induced cytotoxicity and found no measurable 
deleterious effect, especially when compared to other ARVs used in the same study. In 
chapter two, the permissiveness of cardiomyocytes to HIV infection as well as the 
relationship between virus-host interaction and caspase-mediated apoptosis were 
investigated. Non-productive, receptor and tropism-independent infection was observed, 
which was arrested after the reverse transcription stage.  However, interaction between the 
virus gp120 and the host’s CXCR-4 chemokine receptor preferentially activated caspase-9 
triggering robust mitochondria-mediated apoptosis. A shift from mitochondrial-initiated, 
caspase-9 mediated to Fas-ligand initiated, caspase-8 mediated was observed when CM were 
co-cultured with HIV-infected MDM. UCLA1 protected against caspase-9 mediated 
  
 
  vii 
 
apoptosis but not caspase-8 mediated. Finally in chapter three I provided answers for the shift 
in caspase activation by showing that supraphysiological levels of IL-1β and IL-6 during HIV 
infection of MDM augment the effects of tumor necrosis factor (TNF). These observation 
provide new insight into the complex pathophysiology of HIVCM and highlight the potential 
of UCLA1 as a novel therapeutic agent to fight HIV and some of its associated diseases. 
 
 
  
 
  viii 
 
ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude to the following people and institutions whose 
contribution was invaluable for the successful completion of this work. 
 
To my main supervisor Dr Makobetsa Khati for entrusting me with this project, for his 
continuous guidance, moral support and patience. He was also a source of inspiration being a 
man with a brilliant mind, exceptional work ethic and very high academic standards. 
To my co-supervisor Prof. Lynn Morris as well as her winning team at the NICD for opening the 
doors of her labs as well as guidance and insight into the complex world of HIV infection and 
host immunity. 
To my co-supervisor Prof. Bongani Mayosi for his guidance and insight in the field of HIVCM. 
To all my lab mates with whom I shared many pleasant times and intellectual discussions. 
To Mary Poshwa at the NICD for providing me with cultured HIV strains as well as assistance 
with p24 assays. 
To the CSIR for their scholarship, research facilities and support staff. 
I acknowledge the generous donation of UCLA1 aptamer by William James, Ian McGowan and 
Brian Sproat under the NIH Aptamer Microbicide Program, grant number 5U01AI066734-03.  
 
I also thank the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH, USA for providing ARVs. 
 
This work was funded by the Department of Science and Technology (DST) and the Council for 
Scientific and Industrial Research (CSIR) through the Thematic and Parliamentary Grants. 
 
  
 
  ix 
 
TABLE OF CONTENTS 
DECLARATION..…………………………………………………………………………….ii 
DEDICATION………………………………………………………………………………..iii 
PUBLICATIONS……………………………………………………………………………..iv 
PRESENTATIONS……………………………………………………………………………v 
ABSTRACT…………………………………………………………………………………..vi 
ACKNOWLEDGEMENTS…………………………………………………………………viii 
TABLE OF CONTENTS……………………………………………………………………..ix 
LIST OF TABLES.…………………………………………………………………...……..xiv 
LIST OF FIGURES......……………………………………………………….………..……xv 
ABBREVIATIONS…………………………………………………………………….......xvii 
CHAPTER ONE 
INTRODUCTION……………………………………………………………………………...1 
1.1 - The epidemiology of HIV/AIDS…………………….…………………………..2 
1.2 - AIDS pathogenesis and HIV-associated cardiomyopathy..……………………...5 
1.2.1 AIDS pathogenesis…………………………………………………….5 
1.2.2 Cardiac Involvement during HIV infection……………………………7 
1.2.3 HIV infection of cardiomyocytes and apoptotic triggers…………….10 
1.2.3.1 TNF, IL-1β and IL-6: the deadly trio of cytokines………..…12 
1.2.3.2 TNF signalling and CM apoptosis…………………………...14 
1.2.3.3 IL-1β and IL-6: complementing TNF in cardiac morbidity.....16 
1.2.4 The role of caspases in cardiomyocyte apoptosis during HIV 
infection………………………………………………………………19 
1.2.4.1 Caspase-9: the canonical caspase in the intrinsic mitochondrial 
death pathway……………………...…………………………20 
1.2.4.2 Caspase-8 and extrinsic death receptor apoptotic pathway…..22 
  
 
  x 
 
1.3 - HAART to heart: Implication of ARVs to HIVCM – a paradigm of AIDS       
 pathogenesis……………………………………………………………….…….22 
1.3.1 Molecular mechanism of HAART-induced cardiovascular disease....23  
1.3.2 Decreased cardiovascular risk of novel classes of antiretrovirals…....26 
1.4 - HIV neutralizing aptamers as tools for HIV research and therapy…..…………29 
1.4.1 Aptamers and the SLEX process…………………………….……….29 
1.4.2 HIV-1 neutralizing aptamers as drugs candidates against AIDS 
pathogenesis and HIVCM……………………………………………31 
1.4.3 The future of aptamers in HIV therapy………………………………33 
1.5 – Objectives of this study.......................................................................................35 
 
CHAPTER TWO 
CYTOTOXICOLOGICAL ANALYSIS OF A GP120 BINDING APTAMER WITH CROSS-
CLADE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENTRY INHIBITION 
PROPERTIES: COMPARISON TO CONVENTIONAL 
ANTIRETROVIRALS………………………..………………………………………………..36 
Chapter Summary……....…………………………………………………………………….37 
1.0 - Introduction…………………………………..…………………………………38 
2.0 – Materials and methods…………………………………………………………41 
2.1 ARVs……………………………………………………………………..41 
2.2 In vitro transcription and validation of monoclonal aptamers…………...41 
2.3 Recombinant HIV-1Ba-L gp120…………………………………………42 
2.4 Culture and phenotyping of human cord-blood stem cell-derived 
cardiomyocytes………………………………………………………...…42 
2.5 Isolation and cultivation of human peripheral blood mononuclear cells 
(PBMCs)………………………………………………………………….43 
2.6 Cell viability……………………………………………………………...44 
2.7 Caspase 3/7 activity……………………………………………………....45 
2.8 Monoamine oxidase A & B enzyme activity assay………………………46 
2.9 Cytochrome P4503A4 activity…………………………………………...46 
2.10 Real-time PCR for quantification of mitochondrial DNA toxicity……..47 
  
 
  xi 
 
3.0 – Results 
3.1 Effects of B40 in comparison to ARVs on viability of human PBMCs 
      and cardiomyocytes………………………………………………………51 
3.2 Cell death was caspase-independent……………………………….…….54 
3.3 Aptamers did not affect levels of MAO enzymes A and B………………55 
3.4 B40 aptamer did not affect the level of CYP450 3A4 enzyme…………..57 
3.5 B40 aptamer did not cause mitochondrial DNA toxicity……….………..58 
4.0 – Discussion………………………………….......………………………………60 
 
CHAPTER THREE 
HIV-1 UNPRODUCTIVELY INFECTS HUMAN CARDIOMYOCYTES AND INDUCES 
APOPTOSIS THAT CAN BE MITIGATED BY AN ANTI-GP120 APTAMER.........................65 
 
Chapter Summary.....................................................................................................................66 
1.0 – Introduction.........................................................................................................67 
2.0 – Materials and methods........................................................................................69 
2.1 Cell cultures................................................................................................69 
2.2 HIV-1 isolates............................................................................................70 
2.3 Antiretrovirals............................................................................................70 
2.4 UCLA1 anti-gp120 monoclonal aptamer...................................................70 
2.5 PCR detection of proviral DNA.................................................................71 
2.6 Detection and modulation of HIV-1 initiated apoptosis in cultured CM by 
TUNEL.......................................................................................................71 
2.7 Cardiomyocyte apoptosis in HIV-infected MDM co-cultures...................72 
2.8 Indirect immuno-fluorescence for Cytochrome c release detection in HIV-
exposed CM................................................................................................73 
2.9 Caspase-8 and -9 enzyme activity and cell viability..................................74 
  
 
  xii 
 
3.0 – Results  
3.1 HIV-1 infection of CM is co-receptor independent and abortive..............75 
3.2 Apoptosis of CM is HIV-1 tropism-dependent and is triggered 
predominantly by the interaction of HIV-1 with the CXCR4....................78  
3.3 The extrinsic or death-receptor pathway is the preferred apoptotic 
mechanism in CM co-cultured with HIV-infected MDM..........................80 
3.4 The intrinsic or mitochondrion-initiated apoptosis is the preferred death-
signal pathway mediated by caspase-9 activation......................................81 
4.0 – Discussion...........................................................................................................87 
 
CHAPTER FOUR 
 
ABERRANT PRODUCTION OF TNF, IL-1β AND IL-6 CYTOKINES BY HIV-INFECTED 
MACROPHAGES TRIGGERS CARDIOMYOCYTE APOPTOSIS AND IS RESTORED BY 
UCLA-1....................................................................................................................................92 
 
Chapter Summary.....................................................................................................................93 
1.0 – Introduction.........................................................................................................94 
2.0 – Materials and methods........................................................................................97 
2.1 Cells, virus and antibody............................................................................97 
2.2 Culture conditions......................................................................................98 
2.3 Virus infectivity assays..............................................................................98 
2.4 Identification and quantification of cytokine expression by multiplex flow 
cytometry..................................................................................................99 
2.5 Cell viability assay...................................................................................99 
  
 
  xiii 
 
2.6 Neutralization of IL-1β, IL-6 and TNF activity in HIV-infected MDM-
uninfected CM co-cultures.......................................................................100 
2.7 Treatment of CM with recombinant cytokines.........................................101 
3.0 – Results 
3.1 UCLA1 inhibits viral replication in PBMCs............................................102 
3.2 TNF, IL-1β and IL-6 are strongly up-regulated during HIV infection and 
are restored to pre-infection levels by the UCLA1 aptamers...................103 
3.3 CM apoptosis in the uninfected CM /HIV-infected MDM co-culture 
system was inhibited by UCLA1 or the simultaneous neutralization of IL-
1β, IL-6 and TNF.....................................................................................109 
3.4 The cytotoxic effects on CM during co-culture with HIV-infected MDM 
can be mimicked in healthy, uninfected CM with recombinant TNF, IL-1β 
and IL-6....................................................................................................112 
4.0 – Discussion.........................................................................................................113 
 
CHAPTER FIVE 
SUMMARIZING DISCUSSION AND CONCLUSIONS.......................................................118 
 
APPENDIX A 
Publication: Antimicrobial Agents and Chemotherapy, July 2009, p 3056-3064  
    doi: 10.1128/AAC.01502-08......................................................................129 
 
APPENDIX B 
Ethical Clearance Certificate.................................................................................................138  
 
GENERAL REFERENCES........................................................................................139 
  
 
 
  xiv 
 
LIST OF TABLES 
Chapter 1 
 Table 1. Cardiovascular complications of FDA approved antiretrovirals.......25 
Chapter 2 
Table 1. Maximum blood plasma concentration (Cmax) and in vitro data of 
   ARVs.................................................................................................49                                                                                                                                                              
Chapter 3 
Table 1.  HIV-1 infection of cultured human CM and primary PBMCs.........76 
Chapter 4 
Table 1. Dose-dependent cytokine-induced cytotoxicity of CM...................112 
  
 
  xv 
 
LIST OF FIGURES 
Chapter 1 
Figure 1. A global perspective of HIV infection...............................................4 
Figure 1.2. Extrinsic and intrinsic apoptotic pathways...................................21 
Figure 1.3. Schematic representation of possible and current drug-targeting 
sites during the various stages of the virus life cycle, from entry to virion 
maturation.........................................................................................................28 
Figure 1.4. Diagrammatic representation of the SELEX process....................30 
Figure 1.5. Space-filling models of an estimated comparison between a 
human IgG antibody and an anti-thrombin aptamer.........................................31 
 
Chapter 2 
Figure 1: Phenotyping of human cord-blood stem-cell derived 
cardiomyocytes.................................................................................................52 
Figure 2:  Effect of B40 aptamer in comparison to a panel of 17 ARVs on 
viability of human cardiomyocytes and PBMCs..............................................53 
Figure 3: Caspase 3/7 activation upon ARV exposure....................................54 
Figure 4: MAO A and B enzyme modulation by B40 aptamer and T20 in 
cardiomyocytes and PBMCs............................................................................56 
Figure 5: Effect of B40 aptamer and T20 in CYP3A4 enzyme activity in 
cardiomyocytes and PBMCs............................................................................57 
Figure 6: Effect of B40 aptamer and T20 on mitochondrial toxicity as 
measured by mtDNA:nDNA ratio in cardiomyocytes and PBMCs.................59 
 
  
 
  xvi 
 
Chapter 3 
Figure 1: Kinetics of HIV infection of CM and PBMC..................................77 
Figure 2: Quantification of the relationship between chemokine co-receptor 
utilization and apoptosis initiation by TUNEL staining of CM, 3 days post 
infection with HIV-1........................................................................................79 
Figure 3: CM apoptosis in a co-culture model with HIV-infected MDM…...81 
Figure 4: Cytochrome c release in HIV-infected CM….………...………….84 
Figure 5: caspase-8 and -9 activity in CM infected with HIV-1.....................85 
 
Chapter 4 
Figure 1. Neutralization of HIV-1CM9 infectivity by UCLA1.......................102 
Figure 2: Cytokine profiling during HIV-1CM9 infection.......................105-107 
Figure 3: Cell viability during HIV-1CM9 infection.......................................110 
Figure 4: Protection of CM from apoptosis with neutralizing antibodies 
directed against TNF, IL-1β and IL-6 in the HIV-infected MDM + uninfected 
CM co-culture model......................................................................................111 
 
  
 
  xvii 
 
ABBREVIATIONS 
 
3TC   Lamivudine 
µg   Microgram 
ABC   Abacavir 
AIDS   Acquired Immunodeficiency Syndrome 
AMD3100  Plerixafor 
AMP   Amprenavir 
ARVs   Antiretrovirals 
AZT   Zidovudine 
B40   gp120 neutralizing RNA aptamer 40 
bFGF   basic Fibroblast Growth Factor   
CCR3, 5  Chemokine (C-C motif) receptor 3, 5 
CD 4, 8, 68  Cluster of Differentiation 4, 8, 68 
CM   Cardiomyocytes 
CXCR4  Chemokine (C-X-C motif) receptor 4 
CYP4503A4  Cytochrome Oxidase 450 3A4 
D4T   Stavudine 
DC-SIGN  Dendritic cell-specific Intracellular Adhesion Molecule-3  
grabbing non-integrin 
ddC   Dideoxycytidine 
DMEM  Dulbecco’s Modified Eagle’s Media 
DNA   Deoxyribonucleic acid 
DRV   Darunavir 
EDTA   Ethylenediamine Tetra Acetic Acid 
EFV   Efavirenz 
ELISA   Enzyme-linked Immunoabsorbent Assay 
FACS   Fluorescence-Activated Cell Sorting 
GM-CSF  Granulocyte Monocyte Colony Stimulating Factor 
G-CSF   Granulocyte Colony Stimulating Factor 
gp120, gp41  glycoprotein 120 Kda, 41 Kda 
HAART  Highly Active Antiretroviral Therapy 
HIV-1, 2  Human Immunodeficiency Virus type-1, 2 
  
 
  xviii 
 
HIVCM  HIV-associated Cardiomyopathy 
i.e   id est, that is 
IFN-γ   Interferon γ 
IC50/EC50  50 % inhibitory concentration 
IgG   Immunoglobulin G 
IL-1β,  2, 4, 5, 6, 7 Interleukin-1β, 2, 4, 5, 6, 7, 8, 9, 10, 13, 15, 17 
8, 9, 10, 13, 15, 17 
IND   Indinavir 
iNO   inducible Nitric oxide Synthase 
IP-10   Inflammatory Protein 10 
LPV   Lopinavir 
LTR   Long Terminal Repeat 
MAO-A, B  Monoamine Oxidase A, B 
MCP-1  Monocyte Chemotactic protein 1 
MDM   Monocyte-Derived Macrophages 
mg   Milligram 
MIP-1α, β  Macrophage Inflammatory Protein α, β 
MTC Mother-to-child 
mtDNA  mitochondrial DNA 
NEV   Nevirapine 
NFV   Nelfinavir 
nM   nanomolar 
NNRTIs  Non-nucleoside Reverse Transcriptase Inhibitors 
NO   Nitric Oxide 
NRTIs   Nucleoside Reverse Transcriptase Inhibitors 
p24   Gag protein 24 Kda 
p38 MAPK  Mytogen Activated Protein Kinase 38 
PDGF   Platelet-derived Growth Factor 
PBMCs  Peripheral Blood Mononuclear Cells 
PBS   Phosphate Buffered Saline 
PHA   Phytohemagglutinin 
PCR   Polymerase Chain Reaction 
PIs   Protease Inhibitors 
  
 
  xix 
 
RNA   Ribonucleic Acid 
r/t   room temperature 
RT-PCR  Real-Time PCR 
SQV   Saquinavir 
ROS   Reactive Oxygen Species 
RTV   Ritonavir 
SPR   Surface Plasmon Resonance 
T-20   Enfuvirtide 
TCID50  50 % Tissue Culture Infectious Dose 
TDF   Tenofovir 
TNF-α   Tumor Necrosis Factor α 
TNF-R1  TNF soluble Receptor 1   
TPV   Tipranavir 
TUNEL  Terminal Deoxynucleotidyl dUTP Nick-End Labelling 
VEGF   Vascular Endothelial Growth Factor 
Z-LEHD-FMK Z-Leu-Glu(O-Me)-His-Asp(O-Me) fluoromethyl ketone 
Z-IETD-FMK Z-IIe-Glu(O-Me)-Thr-Asp(O-Me) fluoromethyl ketone 
 
Chapter One: Introduction 
 
 
  1 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One: Introduction 
 
 
  2 
 
1.1 – The epidemiology of HIV/AIDS 
 
Human immunodeficiency virus (HIV) is the aetiological agent of Acquired Immune 
Deficiency Syndrome (AIDS) which has cumulatively infected approximately 65 
million people and caused an estimated 25 million deaths worldwide since it was first 
identified in 1983 (Barre-Sinoussi et al., 1983). According to the UNAIDS 2009 
report an estimated 31.1 million - 35.8 million people are currently infected with the 
virus, of which approximately 25 million live in Sub-Saharan Africa accounting for 
64% of all people living with HIV (Figure 1). In Africa, during 2008 alone it was 
estimated that 1.6 million – 2.2 million people became newly infected by HIV and 2 
million lost their lives to AIDS in 2008 alone (UNAIDS, 2009). 
 
Globally, heterosexual transmission remains the dominant mode of transmission, 
accounting for 85 % of all HIV infections. Outside sub-Saharan Africa, a third of all 
HIV infections are acquired by needle-sharing amongst intravenous drug users, 
mostly in Southeast Asia and Eastern Europe (UNAIDS, 2009). 
 
A disconcerting feature of the pandemic in the last decade is the disproportional 
number of new infections in women and young people between the ages of 15-24 
years, which currently account for half of all new infections. Women now make up 
about 42 % of those infected worldwide and over 70 % in sub-Saharan Africa 
(UNAIDS, 2009). The rising incidence and prevalence of HIV in women of child-
bearing age has led to an increase in the number of children infected. An estimated 3.5 
million children had vertically acquired HIV by the end of 2005, of which 3 million 
live in Sub-Saharan Africa alone (UNAIDS, 2009).  
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Despite some efforts, South Africa’s AIDS epidemic is one of the worst in the world 
and shows no signs of decline. Approximately 6.1 million people, representing 20.7 % 
of the total population were estimated to be HIV positive, resulting in 360,000 deaths 
by the end of 2005 alone (UNAIDS, 2009). By the end of 2004, a third of pregnant 
women who attended public antenatal clinics were infected and trends overtime show 
a gradual increase in HIV prevalence. This has resulted in a mother-to-child (MTC) 
HIV infection of half a million children in 2008 (UNAIDS, 2009). 
 
In spite of the rising number of new infections, there are increasing numbers of 
countries reporting stabilisation or declines in HIV prevalence (e.g. Zambia, 
Tanzania, Kenya, Ghana, Rwanda, Burkina Faso and Zimbabwe). However, 
increasing morbidity and mortality rates coupled with a maturing HIV epidemic must 
be taken into account when interpreting data (Simon, Ho, and Abdool Karim, 2006). 
Moreover the apparent decline in prevalence may be brought about by the number of 
HIV-related fatalities which is higher in some regions than those of new infections. 
However, behavioural change cannot be ignored and has contributed significantly to 
the decline in new HIV infections (Gregson et al., 2006). 
 
The current reality is that HIV/AIDS morbidity and mortality continue to increase at a 
very fast pace in Sub-Saharan Africa, particularly in South Africa. Unless this 
increase is curtailed, the impact of HIV/AIDS is expected to more than double the 
burden of premature mortality by the year 2010 (Bradshaw et al., 2003). 
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Figure 1: A global perspective of HIV infection (UNAIDS report, 2009) 
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1.2 – AIDS pathogenesis and HIV-associated cardiomyopathy 
 
1.2.1 – AIDS pathogenesis  
 
HIV-1 started as a zoonosis, originating from primates infected with the Simian 
Immunodeficiency Virus (SIV), although through natural selection and 
immunological pressure in the new host, HIV diverged from SIV (Zhu et al., 1998, 
Gao et al., 1999, Korber et al., 2000, Marx et al., 2001). Transmissions between 
humans can take place either vertically, from mother-to-child (MTC) or horizontally, 
from sexual contact. Heterosexual intercourse accounts for the largest number of 
infections worldwide and is the major drive of the HIV-pandemic (Kilmarx, 2009). 
Contaminated blood products, particularly contaminated blood in blood banks, re-
using of needles in low-resource countries and needle-sharing amongst intravenous 
drug users are also important routes of transmission (Kilmarx, 2009). However, the 
ability of an exposed individual to became infected depends on a large number of 
factors, not only host and viral but also environmental. Nonetheless, when HIV-1 
escapes the host’s natural barriers, it establishes an infection primarily in CD4+ T 
lymphocytes. In the first 4 to 8 weeks following exposure, the virus replicates 
unabatedly reaching very high viral loads while the patient remains asymptomatic 
(Ford, Puronen, and Sereti, 2009). It is mainly at this stage that viral reservoirs are 
established (Siliciano and Siliciano, 2000). These consist of quiescent, mostly CD4
+
 
cells that are infected but their dormant state, does not allow for viral replication. The 
virus undergoes reverse transcription and integrates into the genome but can only 
begin replicating when the cells are activated. Quiescent cells can remain in this state 
for decades, thereby perpetuating the infection.  
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The clinical scenario of the newly infected individual changes upon sero-conversion, 
when the body’s adaptive branch of the immune system begins to produce 
neutralizing antibodies against the circulating virus resulting in a sharp decline in viral 
load (Ford, Puronen, and Sereti, 2009). At this stage fever, lymphadenopathy, 
pharyngitis and myalgia set in. Some cases are severe enough to merit hospitalization. 
However, this state of malaise resolves within a few days and the patient returns to 
normal but the struggle between the immune system and the virus has just begun. T-
cell depletion occurs not only due to the budding out process of virions from infected 
cells but also as a result of chronic immune activation (Miura and Koyanagi, 2005). 
The presence of virus and viral proteins increase the expression of TNF superfamily 
ligands and their receptors in T-cells and macrophages which can in turn induce 
apoptosis in bystander cells (Campbell et al., 2004; Ma and Woolf, 1995; Zhang et al., 
2001). This mechanism of cellular depletion accounts for most of the T-cell and 
macrophage loss. It is also likely that this process contributes to cell apoptosis in 
many different tissues. Recent work, including my own, has shown that an almost 
identical mechanism accounts for cardiomyocyte apoptosis in cultured cells (Fiala et 
al., 2004b; Twu et al., 2002). It is therefore likely that cardiovascular damage takes 
place at this early stage of HIV-1 infection. 
 
The progressive loss of T-lymphocytes and macrophages goes unnoticed for 
approximately 9±2 years in adult patients according to clinical trials and cohort 
studies (Mellors et al., 1997; Egger et al., 2002; Jaén et al., 2008), thought the 
progression to AIDS and risk of death is faster in low-income countries (Braitstein et 
al., 2006). Generally speaking, immunosuppression becomes of clinical concern once 
the CD4
+
 cell count drop from 1,500 cells/μl to below 200 cells/ μl. The onset of 
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immunosuppression brings an array of opportunistic diseases. The patient falls ill 
frequently and for long periods of time. If left untreated, the life expectancy is less 
than two years. Between the onset of AIDS and death, cardiomyocyte destruction 
becomes more pronounced as do AIDS-related neuropathies (Highleyman, 2009).  
Approximately 10 % of untreated patients are suspected to succumb to cardiovascular 
complications (Barbaro, 2003; d'Amati, di Gioia, and Gallo, 2001; Ntseke and 
Mayosi, 2009), although most lose their lives to upper-respiratory tract infections and 
tuberculosis (UNAIDS, 2009).   
 
1.2.2 – Cardiac involvement during HIV infection 
 
The link between HIV-infection and cardiac disease was recognized as early as 1983 
(Autran et al., 1983) but its prevalence is still a matter of much debate. Nonetheless, 
incidence rates ranging from 28 % to 73 % have been reported prior to the 
introduction of highly active antiretroviral therapy (HAART) (Anderson et al., 1988; 
Baroldi et al., 1988; d'Amati, di Gioia, and Gallo, 2001; Reilly et al., 1988). However, 
cardiac involvement in AIDS patients was not clinically significant and the majority 
of cases were only detected at the time of autopsy. Furthermore, cardiac disease in 
HIV positive individuals is often clinically silent, reversible and usually 
overshadowed by clinical manifestations in other organs, primarily the lungs and 
brain. Therefore the number of significant cardiac disease during life represents a very 
small, albeit rapidly increasing percentage, of cardiac disease detected at necropsy 
(Sudano et al., 2006). 
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There are a number of studies that have examined the epidemiology, clinical 
presentation, and outcome of HIV-associated cardiovascular disease in Africa 
(Magula and Mayosi, 2003; Mutimura et al., 2008; Ntsekhe and Hakim, 2005; 
Ntsekhe and Mayosi, 2008). The studies confirmed that cardiac abnormalities are 
more common in HIV-infected people, compared to normal controls, and that about 
half of hospitalized patients and a significant proportion of patients followed up over 
several years develop cardiac abnormalities. The commonest HIV-related cardiac 
abnormalities identified to date were cardiomyopathy, pericarditis and myocarditis 
(Barbaro, 2003, Netseke and Mayosi, 2009). Tuberculosis was the major cause of 
large pericardial effusion in Africa (Cegielski et al., 1990; Taelman et al., 1990; 
Reynolds et al., 1992; Hsia and Ross., 1994; Pozniak et al., 1994; Maher et al., 1997; 
Mayosi et al., 2008). However, due to the very limited data on the pathogenesis of 
cardiomyopathy in Africa, particularly lack of evidence from cardiac histology, it is 
difficult to determine to which extent opportunistic infections other than TB lead to 
cardiovascular dysfunction. Viral myocarditis has been suggested as a significant 
cause of cardiac morbidity (Paravinci et al., 1991), but protozoan and bacterial 
opportunistic pathogens have been found at the time of autopsy in the African context 
(Anderson et al., 1988; Longo-Mbenza et al., 1998). In one study involving 16 
subjects in the DRC identified toxoplasmosis and cryptococcosis in 40% of cases of 
HIV-associated cardiomyopathy (Longo-Mbenza et al., 1998). However, due to its 
sample size and restricted geography location, this data should be interpreted with 
caution and broad generalizations regarding the identity of cardiac pathogens should 
be avoided. 
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There is a growing body of evidence that points to a direct link between HIV infection 
and cardiovascular disease, independently of opportunistic infections and 
immunodeficiency in the clinical setting (Grody, Cheng, and Lewis, 1990; Rodriguez 
et al., 1991; Herskowitz et al., 1994; Lipshultz et al., 1990) and experimental models 
(Fiala et al., 2004; Kan et al., 2005; Kan, Xie, and Finkel, 2000; Kan, Xie, and Finkel, 
2006; Twu et al., 2002). 
 
The lack of resources has limited the diagnosis of cardiovascular dysfunction to non-
invasive imaging techniques (electrocardiography, ecography and X-ray) which 
provide very limited information on the etiology of the disease which also decreases 
treatment options. Nonetheless, there are three distinct clinical presentations of 
HIVCM, distinguishable by the evolution of the disease in the patient from 
asymptomatic to hospitalized (Ntseke and Mayosi, 2009).  Left ventricular 
dysfunction is the hallmark of HIVCM, which is usually asymptomatic in it’s early 
stages and is associated with a range of abnormalities such as dilated ventricles with 
impaired systolic function, non-dilated ventricles with evidence of impaired diastolic, 
non-dilated ventricles with impaired diastolic function, dilated cardiac chambers with 
normal ejection fraction (Hakim et al., 1997; Nzuobontane et al., 2002; 
Twagirumukiza et al., 2007; Longo-Mbenza et al., 1997; Felker et al., 2000; Niakara 
et al., 2002; Longo-Mbenza et al., 1995; Longo-Mbenza et al., 1998). A slightly 
different clinical presentation is highlighted by heart failure with evidence of dilated 
ventricles and depressed systolic function, which is strongly associated with severe 
immunodeficiency, indicated by CD4
+
 T-cell counts below 100 cells/μl (Currie et al., 
1995; Hakim et al., 1997; Nzuobontane et al., 2002; Twagirumukiza et al., 2007). A 
third scenario of HIVCM is observed in hospitalized patients with advanced AIDS 
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and opportunistic infections, where patients develop heart failure in the absence of a 
clinical history of heart disease (Ntseke and Mayosi, 2009).  
A well described cardiovascular complication of HIV infection is ischemic heart 
disease (Matetzky et al., 2003; Lohse et al., 2007; Grinspoon et al., 2008). The 
etiology of the disease, as with most other cardiovascular problems is poorly 
understood. Recently, two studies were undertaken with the aim of gaining more 
insight into the pathophysiology of this disease (Becker et al., 2010; Becker et al., 
2010b). In these two studies, HIV-positive, treatment naïve patients with acute 
coronary syndrome were found to be younger, had similar traditional risk factors and 
a lower artherosclerotic burden but higher thrombotic burden than HIV-negative 
patients with the same condition. Serological data showed that HIV positive patients 
had higher frequencies of anticardiolipin and antiprothrombin antibodies, lower levels 
of protein C and higher levels of factor VIII. This data suggests a prothrombic state in 
the pathogenesis of acute coronary syndromes which could be related to chronic 
immune activation and bacterial translocation. 
 
 
1.2.3 –HIV-1 infection of Cardiomyocytes and apoptotic triggers 
 
Studies in this area are still in its infancy but there is mounting evidence to suggest 
that HIV infection is capable of causing cardiac myocyte apoptotic death (Chaves et 
al., 2003; Chen et al., 2002; Kan et al., 2005) (Fiala et al., 2004a) (Fiala et al., 2004b); 
(Kan, Xie, and Finkel, 2006). However, the exact aetiology remains controversial, as 
is the potential relationship of intramyocardial HIV-infected cells to the development 
of cardiac pathology (Chaves et al., 2003); (Fiala et al., 2004b). What is certain is that 
Chapter One: Introduction 
 
 
  11 
 
HIV has been found to productively infect infiltrating inflammatory cells, 
macrophages and lymphocytes in heart tissue of HIV positive individuals and a 
correlation was established between the extent of macrophage infiltration and the risk 
of HIVCM (Liu et al., 2001). Infection of cardiomyocytes by HIV is relatively well 
documented and has been described in vivo (Grody, Cheng, and Lewis, 1990; 
Herskowitz et al., 1994). However, in vitro data in animal models points to a non-
productive infection (Fiala et al., 2004b; Twu et al., 2002). Interestingly,  Rebolledo 
and colleagues reported that HIV-1 does not infect but efficiently replicates in human 
foetal cardiac myocytes 14 to 18 weeks old (Rebolledo et al., 1998). Infection was 
only achieved with a VSV-G-pseudotyped HIV-1 vector.  
The mechanism by which HIV induces apoptotic death in cardiac tissue is still a 
question of much debate and very few studies have been carried out to date to provide 
any definite answers. A combination of virokines, cytokines, in situ productive 
infection of infiltrating macrophages and non-productive HIV infection of 
cardiomyocytes all seem to play a role in pro-apoptotic signalling, involving the 
components of both mitochondrial and death receptor pathways (Barbaro et al., 1999; 
Raidel et al., 2002; Twu et al., 2002). 
 
Cardiomyocyte apoptosis is also likely to be triggered by infiltrating, HIV-infected 
macrophages via the extrinsic or death-receptor pathway (Twu et al., 2002). These 
activated macrophages secrete an array of inflammatory mediators of which TNF-α 
(tumour necrosis factor) and COX-2 (cyclooxygenase) play the major role in extrinsic 
apoptotic signalling (Liu et al., 2001). The binding of TNF-α and Fas ligand to their 
respective receptors leads to caspase 8 activation and phagocytosis of the target cell.  
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To date, it is not yet known which mechanism plays a greater role in cardiomyopathy, 
the most common form of HIV-induced cardiac disease. Most argue that HIV-infected 
infiltrating macrophages play a much more significant role than direct (intrinsic) 
pathogen action (Barbaro, Fisher, and Lipshultz, 2001; Twu et al., 2002). There is 
indeed much evidence to support this argument. However it is important to highlight 
the fact that to my knowledge, all in vitro studies were carried out using rat tissue, 
either neonatal ventricular myocytes or mice embryonic stem cells induced to 
differentiate into cardiomyocytes. While these murine models have proved to be 
relatively accurate, they do not mimic human cardiac tissue. 
 
Furthermore, all work done to date on human cardiac tissue was carried out on 
paraffin-embedded formalin fixed tissue using a combination of 
immunocytochemistry, riboprobe hybridization, PCR and apoptosis assays (Fiala et 
al., 2004b; Liu et al., 2001; Twu et al., 2002). The complexities of a failing heart 
coupled to the time lapsed between death and tissue extraction from biopsies takes a 
toll in the integrity of the quality of the sample. These variables would not be very 
relevant if the difference between intrinsic and extrinsic tissue damage was clear cut.   
 
1.2.3.1 – TNF, IL-1β and IL-6: the deadly trio of cytokines  
 
The vast majority of cytokines including the ones discussed here are pleitrophic in 
nature and for this reason, I will only focus on their role in the degeneration of the 
cardiovascular system and progression to HIVCM.  
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Cytokines belong to a superfamily of proteins, comprising more than 100 members 
and are secreted by most cells, playing an essential role in angiogenesis, auto-immune 
diseases, inflammation and tumor growth. All cytokines signal through 7-helix G-
protein coupled receptors and most of these receptors exhibit heterogeneous binding 
properties whereby several cytokines may bind to the same receptor and elicit 
different responses, sometimes even antagonistic responses. The most important 
cytokine-producing cells during HIV-infection and progression to HIVCM are tissue 
MDM. HIV-infected, infiltrating tissue MDM exhibit a cytokine profile that is not 
only conducive and suppressive of HIV infection and replication but also act in a 
paracrine fashion resulting in prolonged inflammation and tissue damage (Fantuzzi, 
Belardelli, and Gessani, 2003; Kedzierska et al., 2003). The pleiotropic nature of 
many cytokines as well as their dependence on other cytokines, has made linking 
cytokines as well as cytokine receptors to cardiovascular morbidity a slow and 
arduous process. Furthermore, most of the knowledge of cytokine-linked 
cardiovascular complications arises from work undertaken in non-HIVCM patients. 
Nevertheless, the tumor necrosis family of cytokines and receptors have been 
identified as key modulators as have the pro-inflammatory cytokines IL-1β and IL-6 
(Barbaro et al., 2000; Fiala et al., 2004b; Finkel et al., 1992; Long, 2001; Monsuez et 
al., 2007; Satoh et al., 1996; Wollert and Drexler, 2001). The CXCR4 chemokine 
receptor has been recently linked to CM apoptosis but it has been recognized as an 
apoptotic receptor in MDM for over a decade (Herbein et al., 1998; Yuan et al., 
2008). Interestingly however, its natural ligand, the chemokine stromal-cell-derived 
factor 1 (SDF-1) is a strong inhibitor of HIV infection and has not been linked to 
apoptosis initiation in either CM or MDM (Bleul et al., 1996; Oberlin et al., 1996).  
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1.2.3.2 - TNF signalling and CM apoptosis 
 
This soluble cytokine, which under physiological conditions is mostly secreted by 
macrophages was the first cytokine identified and was named after its properties of 
inducing extensive cytotoxicity in several tumor cell lines as well as necrosis in 
certain animal models of cancer (Carswell et al., 1975; Granger et al., 1969; Kolb and 
Granger, 1968). The members of this superfamily span 27 receptors and 18 ligands 
(Locksley, Killeen, and Lenardo, 2001), but TNF exerts its biological apoptotic role 
by interacting with their cognate receptors, namely the TNF-receptor 1 and 2 
(Locksley, Killeen, and Lenardo, 2001). Both receptors bind membrane bound as well 
as soluble ligand. TNF-R1 is constitutively expressed in most cells, but TNF-R2 is 
very tightly regulated and almost exclusively found in the cells of the immune system. 
TNF-R1 is the key receptor of TNF signalling in most cells whereas TNF-R2 assumes 
this role in lymphoid tissue. The importance of TNF-R2 in paracrine signal 
transduction is still poorly understood, but its likely to be minor since it can only be 
activated by membrane-bound and not soluble TNF (Grell et al., 1999). However, the 
extracellular domains of both receptors can be cleaved, resulting in soluble fragments 
with bimodal roles (Xanthoulea et al., 2004). These soluble fragments can either 
neutralize TNF or they can extend its plasma half-life. Furthermore, the proteolytic 
shedding of these receptors also function as a rapid way of down-regulating the 
effects of TNF by reducing receptor density on the cell surface.  
 
The molecular mechanisms of TNF-induced cell death are relatively well understood 
and progresses through activation of NF-κB family of inflammatory transcriptional 
activators (Wajant, Pfizenmaier, and Scheurich, 2003). Nonetheless, TNF-initiated 
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apoptosis plays a comparatively minor role when compared to its central role in 
inflammation and immune-system development. From a pathophysiological 
perspective, high concentrations induce shock-like symptoms and it thus plays a 
pivotal role in septic shock (Mannel and Echtenacher, 2000). On the other hand, 
prolonged exposure to low concentrations can result in cachexia, which is also the 
origin of one of the several names for TNF, cachectin (Beutler et al., 1985). However, 
the systemic toxicity brought about by TNF, as well as most pro-inflammatory 
cytokines involved in HIVCM, is mostly due to cellular mediators such as nitric oxide 
(NO) and not necessarily related to its capability to initiate cell death (Monsuez et al., 
2007).  
The death-signalling cascade is initiated upon TNF binding to its death receptor TNF-
R1. The silencer of death domain (SODD) protein which is bound to the cytosolic 
portion of the receptor and is responsible for relaying the death signal thought its 
death domain (DD), dissociates. The now exposed death domain recruits the death-
domain containing adaptor protein (TRADD) through homophilic interactions. At this 
point, depending whether signal is apoptotic or necrotic in nature, the there is a 
divergence in the downstream event. During necrosis, the TNRF-1-TRADD complex 
serves as a platform for the binding of the death domain-containing serine-threonine 
kinase RIP and the TNF receptor-associated factor 2 (TRAF2). The way in which RIP 
is involved in the production of reactive oxygen species (ROS) is yet unknown, but 
this is the final step in necrotic signalling as ROS lead to extensive and irreversible 
DNA damage, leading to the activation of poly ADP-ribose polymerase 1 (PARP-1). 
This enzyme uses up large quantities of NAD
+
 through the synthesis of poly-ADP 
ribose, leading to ATP depletion, creating conditions favourable to necrosis (Eguchi, 
Shimizu, and Tsujimoto, 1997; Leist et al., 1997). 
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Under apoptotic conditions, the death domain adaptor protein FADD and not RIP is 
recruited to the TNF-R1 cytoplasmic domain. This complex then recruits caspase-8 
through its death-effector domains residing in the amino-terminal region of both 
molecules (Sprick et al., 2000; Yeh et al., 1998; Zhang et al., 1998). The downstream 
effects of this complex are discussed in detail below (section 1.2.5). 
 
There is some contradicting evidence that the purported non-death domain containing 
TNF-R1 also has the capability to induce apoptosis, since studies using TNF-R2-
specific antibodies have shown that this receptor alone is sufficient to initiate cell 
death (Grell et al., 1993; Vandenabeele et al., 1995). However, stimulation of TNF-R2 
by exogenous, soluble ligand is not enough to trigger apoptosis (Grell et al., 1999). 
The signal must be generated by endogenous, membrane-bound TNF. Furthermore, 
the effect of endogenously produced TNF on TNF-R1 is greatly increased by the 
existing stimulation of TNF-R2. 
 
There is a contrasting relationship between TNF-α expression and HIV infection. 
Through activation of NF-κB, TNF-α significantly enhances HIV replication in 
infected cells (Griffin et al., 1991; Naif et al., 1994), but on the other hand, it 
suppresses viral replication in bystander cells, through signalling via the TNF-R2 
(Herbein and Gordon, 1997). 
 
1.2.3.3 - IL-1β and IL-6: complementing TNF in cardiac morbidity  
 
IL-1β and IL-6 will be discussed together because although they do not share 
structural and sequence homology, they are always co-secreted and exert near 
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identical effects in the progression and augmentation of cardiac pathology. Moreover, 
it has been demonstrated that IL-6 induction can be used as an alternative, indirect 
assay system for IL-1β production (Van Damme and Van Snick, 1988). 
 
IL-1β and IL-6 are key mediators of inflammation and are produced by many cell 
types, but mostly by monocytes, macrophages, fibroblasts and endothelial cells upon 
stimulation by pathogens and other pro-inflammatory cytokines including TNF 
(Kishimoto, 1989). High levels of IL-1β and IL-6 are strongly correlated with 
rheumatoid arthritis (de Benedetti et al., 1991; Hermann et al., 1989; Houssiau et al., 
1988; Mayet et al., 1990) and congestive heart failure (Long, 2001; Wollert and 
Drexler, 2001). High concentrations have also been detected in cardiac myxomas and 
cervical and bladder carcinomas (Scheller, Ohnesorge, and Rose-John, 2006). 
Recently, in a 3 year follow up study of patients with acute myocardial infarction IL-6 
(IL-1β was not measured) was identified as a key marker in mortality prediction (Tan 
et al., 2009). In ex-vivo and murine models, IL-1β and IL-6 have been associated with 
decreased cardiac contraction, extensive cardiac remodelling and increased mortality 
(Finkel et al., 1992; Givertz and Colucci, 1998; Li et al., 2005).  Cardiac pathology 
caused by these cytokines is further compounded by their ability to enhance HIV 
replication in chronically infected CD4
+
 T cells as well as in MDM (Kedzierska et al., 
2003), since there is a strong link between productive viral replication and 
cardiovascular morbidity. 
 
The mechanism of signal transduction of IL-6 is mediated by the signal transducing 
protein gp130 (Taga and Kishimoto, 1997). IL-6 first interacts with the membrane 
associated IL-6 receptor (IL-6R), forming an IL-6/IL-6R complex. This complex then 
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binds to gp130, which initiated the signal cascade (Rose-John and Heinrich, 1994). 
IL-6R binding is vital for gp130 interaction and yet some cells that do not express IL-
6R are still responsive to IL-6. This can be explained by the secretion of limited 
quantities of IL-6R. The soluble IL-6R complexes with IL-6 thus enabling gp130 
activation in IL-6R
-
 cells (Mackiewicz et al., 1992; Taga et al., 1989).  
 
IL-1β can also be simply called IL-1, although there are two functional isoforms, α 
and β, the former is more predominant in mice whereas the later in humans and they 
seem to share identical structure and function (Priestle, Schar, and Grutter, 1988; Van 
Damme and Van Snick, 1988), despite sharing less than 30 % sequence homology 
(March et al., 1985). There are minor functional difference between the two forms, 
mostly related to T-cell maturation and differentiation (Fibbe et al., 1989). Their 
signal is relayed through the IL-1 type 1 receptor (IL-1RI), although there is a second 
receptor, IL-1 type II receptor (IL-2RI), but since downstream events cannot be 
detected upon ligand binding, it is considered a decoy receptor.  
 
The signalling cascade of both cytokines that lead to CM morbidity and apoptosis are 
relayed via the p38 MAP kinase pathway inducing the transcription of inducible nitric 
oxide synthase (iNOS) via NF-κB activation (Finkel et al., 1992; Givertz and Colucci, 
1998; Li et al., 2005). The resulting NO exerts its cardiotoxic effects by activating 
guanylate cyclise and increasing cyclic guanosine monophosphate (Vila-Petroff et al., 
1999) resulting in cardiomyocyte shortening velocity. Furthermore, it also impairs the 
function of the Ca ATPase, resulting in an increase in intra-cytoplasmic calcium due 
to ineffective sarcolemmal calcium release as well as inadequate calcium 
sequestration and release from the sarcoplasmic reticulum (Marks, 2003). This 
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prolonged negative ionotropic effect results in caspase-mediated apoptosis (Fiala et 
al., 2004b; Finkel et al., 1992; Twu et al., 2002). 
 
1.2.4 – The role of caspases in cardiomyocyte apoptosis during HIV  
infection 
 
Caspases are an evolutionarily conserved family of cysteinyl proteinases that play key 
roles in cell survival, proliferation and differentiation (Lamkanfi et al., 2007). More 
specifically, the caspase gene family comprises 15 members that can be loosely 
grouped in two major sub-families, regulating two signalling pathways: apoptosis and 
inflammation. The apoptotic sub-group can be further divided into two types: initiator 
(caspases-2, 8, 9 and 10) and executioner (caspases-3 and to a lesser extent 6 and 7). 
For the purpose of this thesis, only the role of caspases in apoptosis will be discussed. 
 
Almost all healthy cells contain several caspases as inactive latent pro-forms called 
precursor zymogens, synthesized as catalytically-quasi-dormant tripartite pro-
enzymes. Initiator caspases contain large N-terminal prodomains consisting of long 
structural motifs containing either a pair of death effector domains (DED, caspase-8 
and 10) or a caspase recruitment domain (CARD, caspases-1, 2, 4, 5, 9, 11 and 12). 
The presence of these prodomains allows for the formation of large multimeric 
complexes resulting in proximity-induced, catalytic auto-activation. There currently 
are four well studied multimeric complexes, namely: the apoptosome, the death-
inducing signalling complex (DISC), the PIDDosome and the caspase-1-containing 
inflammasomes. The executioner caspases, on the other hand, lack these large 
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prodomains and have to be activated by the initiator caspases. In this fashion, initiator 
caspases provide a link between cell signalling and apoptotic execution. 
 
1.2.4.1 – Caspase-9: the canonical caspase in the intrinsic mitochondrial 
death pathway 
 
A broad range of stimuli, some well characterized (such as cytotoxic and oxidative 
stress; heat shock, DNA damage, radiation and growth factor deprivation) and others 
yet to be identified culminate in caspase-9 activation and subsequent apoptosis 
(Figure 1.2). During HIV infection, it is hypothesized that the trigger is either HIV 
entry into cardiomyocytes via endocytosis through the ganglioside GM1 and/or 
Trojan transport system or by direct interaction between cell-free virus and viral pro-
apoptotic proteins with the CXCR4 chemokine receptor (Herbein et al., 1998; Yuan et 
al., 2008). These viral pro-apoptotic factors activate the mytogen activated protein 
kinase (MAPK) pathway by Erk1/2 phosphorylation via the p38 MAPK which results 
in a prolonged negative inotropic effect (change in mitochondrial membrane potential, 
ΔΨ) on cardiac myocytes leading to mitochondrial leakage of cytochrome c into the 
cell cytosol (Figure 1.2) (Fiala et al., 2004b; Kan, Xie, and Finkel, 2006). 
Cytochrome c, together with dATP assemble into the septameric apoptosome with the 
aid of Apaf-1 (apoptotic protease activating factor-1), which forms the central 
scaffold of the complex. Procaspase-9 is then recruited into this complex via the 
CARD domain. The entire complex undergoes dimerization which then results in the 
proteolytic activation of procaspase-9 into caspase-9. The now active, but not free 
caspase-9, cleaves and activates the executioner caspase-3, which in turn, cleaves a 
broad range of key cellular proteins as well as nuclear DNA, resulting in apoptosis. 
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The process leading up to caspase-9 and -3 activation is very tightly regulated by the 
cell and is often the target of viral proteins, since cell survival is imperative for viral 
replication and propagation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Extrinsic and intrinsic apoptotic pathways. Extrinsic cardiomyocyte 
apoptosis occurs when soluble ligand (TNF, Fas-ligand) activates the cell-surface 
death receptor. Pro-caspase 8 is then recruited into the DISC via binding to the FADD 
adaptor protein, where it is proteolitically activated. Mitochondrial mediated apoptosis 
is triggered by binding of gp120 to the CXCR4 chemokine receptor. The resulting 
prolonged ionotropic effect results in Cytochrome c leakage, which together with 
Apaf1, activate caspase-9. Both pathways converge at the activation of caspase-3 
resulting in apoptosis. 
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1.2.4.2 – Caspase-8 and the extrinsic death receptor apoptotic pathway 
 
Caspase 8 signalling begins with the interaction of ligand with a cell surface death 
receptor of the TNF superfamily, usually Fas, CD95 or TNF-R1 (Figure 1.2) (Boldin 
et al., 1996; Muzio et al., 1996). These receptors have death domains in their cytosolic 
domains and recruit two isoforms of procaspase-8 to the DISC via binding to the 
FADD adaptor protein (Figure 1.2). The interactions of the proteins recruited to the 
DISC are dependent on homotypic contacts. The receptor DD interacts with the DD of 
FADD, while the DED of FADD interacts with the N-terminal tandem DEDs of 
procaspase-8. Therefore, the formation of the DISC complex serves as a platform to 
bring the two procaspase-8 isoforms close to each other in favourable mutual 
orientation. These procaspase-8 dimers are now proteolytically active and auto-
activate each other to mature caspase-8. Once the active caspase-8 heterodimer is 
formed at the DISC, the mature caspase-8 is released from the complex into the 
cytosol where it triggers apoptosis (Rupinder, Gurpreet, and Manjeet, 2007; 
Varfolomeev et al., 1998).  
 
1.3 – HAART to heart: Implication of ARVs in HIVCM – a paradigm of AIDS 
pathogenesis 
 
Antiretrovirals are the backbone of HIV therapy. These agents target the virus at 
different stages of its life cycle (Figure 1.2). Currently there are 22 FDA-approved 
antiretroviral agents as well as an array of novel drugs in various stages of clinical 
trials (Temesgen et al., 2006). The current drugs can be sub-divided into four 
categories based on their mode of action. There are nucleotide/nucleoside analogues 
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(NRTIs) that block the viral enzyme reverse transcriptase by competing with the 
natural substrate and causing chain termination in the synthesis of pro-viral DNA 
(Mitsuya et al., 1986). There are also antiretrovirals that function as non-nucleoside 
analogues (NNRTIs), binding to a pocket adjacent to the catalytic pocket of the 
reverse transcriptase enzyme and induce a conformational change that disrupts the 
catalytic site (Merluzzi et al., 1990). 
 
A decade ago a novel antiretroviral was added to the growing arsenal of drugs. These 
were protease inhibitors (PIs) and their introduction had a profound impact on 
mortality and morbidity rates as well as in the quality of life of many HIV positive 
patients (UNAIDS, 2009). The combination of NRTIs, NNRTIs and PIs was coined as 
HAART. PIs work by interfering with the last step of the virus life cycle: maturation 
(Figure 1.2) (Cimarelli and Darlix., 2002).  Upon budding, the virion-encapsulated 
protease cleaves a number of proteins giving rise to mature, infectious viral particles. 
The PIs are encapsulated within the virion and block this step by acting as suicide 
inhibitors in the catalytic domain (Temesgen et al., 2006). The inhibition of the 
protease enzyme prevents maturation of the virions giving rise to non-infections 
particles. 
 
1.3.1 – Molecular mechanisms of HAART-induced cardiovascular disease 
 
The therapeutic benefits of HAART cannot be overstated, however, there is a strong 
correlation between therapy length and the risk of cardiovascular complications 
(Barbaro, 2005). Moreover antiretrovirals belonging to the NRTI, NNRTI and 
especially the protease inhibitor classes are particularly toxic to the cardiovascular 
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tissue (Table 1). This, in part, has to do with their target, the catalytic site of HIV-1 
protease. This binding pocket is homologous to that of host proteins involved in lipid 
metabolism and glucose disposal (Carr et al., 1998a). This allows PIs to interfere with 
cytoplasmic retinoic acid binding protein 1 (CRABP-1) as well as low density 
lipoprotein receptor-related protein (LRP) leading to a decrease in synthesis of cis-9-
retinoic acid and peroxisome proliferator-activated receptor type-γ (PPAR-γ) 
herterodimer (Carr et al., 1998a; Carr et al., 1998c). Under this conditions, an increase 
in adipocite apoptosis coupled with a decreased rate of pre-adipocity maturation into 
adipocites results in a significant increase in lipid release and decrease in triglyceride 
storage. This effect is further enhanced by the inhibition of proteosome activity and 
concomitant accumulation in the intracellular levels of the active subunit of sterol 
regulatory element-binding protein-1c in hepatocytes and adipocites (Mooser and 
Carr, 2001). The well documented impairment of hepatic LRP further interferes with 
chylomicron uptake and endothelial triglyceride clearance (Carr et al., 1998a; Carr et 
al., 1998b). The effects of these metabolic interferences are further compounded by an 
increase in apo C-III (Bonnet et al., 2001) and lipoprotein (a) (Periard et al., 1999). 
Apo C-III was found to be strongly associated with lipodistrophy, whereas lipoprotein 
(a) has been associated with premature atherosclerosis in HIV-negative patients 
(Assmann, Schulte, and von Eckardstein, 1996). Inhibition of the glucose transporter 
Glu4, further impairs glucose uptake in insulin-sensitive tissues thus precipitating the 
emergence of insulin resistance and dyslipidemia (Murata, Hruz, and Mueckler, 
2000).  
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Table 1. Cardiovascular complications of FDA approved antiretrovirals  
ARVS    
Class FDA approval 
date 
Side-effects References 
NNRTIs    
Delavirdine April, 1997 Cardiomyopathy, 
hypertension, dyslipidemia 
(Gill and Feinberg, 
2001) 
Efavirenz September, 1998 Tachycardia, dyslipidemia (Lennox et al., 2009) 
Etravirine January, 2008 Myocardial infarction, 
angina pectoris, dyslipidemia 
(Katlama et al., 2009) 
Nevirapine June, 1996 Dyslipidemia (Rodriguez-Arrondo et 
al., 2009) 
NRTIs    
Abacavir December 1998 Myocardial infarction? 
lipodystrophy 
(Albrecht, 2009) 
Didanosine  Portal hypertension, 
lipodistrophy 
(Ziagen and Videx, 
2008) 
Emtricitabine July 2003 Lipodistrophy, dyslipidemia (Molina et al., 2007) 
Lamivudine November 1995 Lipodistrophy, dyslipidemia (Kumar and Patel) 
Stavudine June 1994 Lipodistrophy, dyslipidemia (Calmy et al., 2009) 
Tenofovir October 2001 Lipodistrophy, dyslipidemia (Stephan, 2008) 
Zidovudine March 1987 Cardiomyopathy, syncope, 
lipodistrophy, dyslipidemia 
(Camsonne, Hurrault 
de Ligny, and Letellier, 
1987) 
Protease 
Inhibitors 
   
Amprenavir April 1999 Lipodistrophy, dyslipidemia (Schooley et al., 2001) 
Atazanavir 
sulphate 
June 1999 Cardiac conduction 
abnormalities, lipodistrophy 
(Feldt et al., 2005) 
Darunavir June 2006 Lipodistrophy, dyslipidemia (Hughes et al., 2009) 
Indinavir March 1996 Lipodistrophy, dyslipidemia (MacDougall, 1996) 
Fosamprenavir  October 2003 Lipodistrophy, dyslipidemia (Hester, Chandler, and 
Sims, 2006) 
Nelfinavir  March 1997 Lipodistrophy, dyslipidemia (Calmy et al., 2009) 
Ritonavir March 1996 Hypertension, hypotension, 
myocardial infarct 
(Calmy et al., 2009) 
Saquinavir  December 1995 Lipodistrophy, dyslipidemia (Calmy et al., 2009) 
Tipranavir June 2005 Lipodistrophy, dyslipidemia (Hughes et al., 2009) 
Fusion Inhibitors    
Enfuvirtide March 2003 None (Wright et al., 2008) 
Entry Inhibitors    
Maraviroc August 2007 Myocardial infarction, 
hypotension  
(Abel et al., 2008) 
Integrase 
Inhibitors 
   
Raltegravir October 2007 None (Lennox et al., 2009) 
* Supplementary information was obtained from the Food and Drug Administration’s 
web site at www.fda.org/oashi/aids/virals.html 
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1.3.2 – Decreased cardiovascular risk of novel classes of antiretrovirals 
 
In the past eight years, three novel drug classes have entered the market. Either by 
coincidence or more strict approval criteria, the incidence of cardiovascular 
complications when compared to other ARVs has decreased significantly (Hughes et 
al., 2009).  
 
The first novel class of drug, Enfuvirtide entered the market in 2003 as a complement 
to HAART in drug-experienced, HIV infected patients (Manfredi and Sabbatani, 
2006). It is marketed under the brand name Fuzeon
®
 and belongs to the class of fusion 
inhibitors, consisting of a linear 36 amino acid peptide homologous to a segment of a 
region of the gp41 coat protein that is crucial for entry (Doms and Trono, 2000) 
(Figure 1.3). It therefore inhibits viral infection of target cells by competing with 
gp41 for the chemokine co-receptors. No negative cardiovascular events have been 
observed in the latest safety and efficacy trials (Wright et al., 2008). 
 
In August of 2007 Maraviroc (Selzentry
®
), a CCR5 co-receptor antagonist was 
approved by the FDA for therapy of treatment-experienced adults with multi-drug 
resistance HIV. This drug is classed as an entry inhibitor and works by blocking the 
interaction of the virion’s gp41 coat glycoprotein with the CCR5 chemokine co-
receptor of the host (Hunt and Romanelli, 2009) (Figure 1.3). A recently published 
review of the clinical literature reported no significant negative cardiovascular 
complications (Abel et al., 2008). 
The latest addition to the arsenal of new classes of ARVs was Raltegravir (Isentress
®
), 
FDA approved in October 2007. This drug belongs to the class of HIV integrase 
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strand transfer inhibitors blocking the integration of pro-viral DNA into the human 
genome (Cocohoba and Dong, 2008). It blocks the strand-transfer step of the 
integration cycle by binding to the active site of the viral integrase enzyme (Espeseth 
et al., 2000; Hazuda et al., 2000) (Figure 1.3). The incidence of cardiovascular 
complications was significantly lower than that reported for NNRTIs, NRTIs and PIs 
(Cocohoba and Dong, 2008). However, this drug has been on the market for less than 
3 years, which is not long enough time to fully evaluate its cardiovascular safety. 
 
Not long ago, the desperation brought about by the failure of the available 
antiretroviral agents made most long-term side effects acceptable. By and large, all 
antiretrovirals have a degree of toxicity that is exacerbated by their prolonged use 
(Temesgen, 2006).  Nowadays in the developed world, HIV infection went from a 
lethal disease to a chronic, manageable ailment further accentuating the side effects 
brought about by chemotherapy. In fact, most complications that arise in HIV positive 
patients on chemotherapy can be directly traced back to the chronic, uninterrupted use 
of antiretrovirals (Temesgen, 2006). Furthermore, conditions like cardiomyopathy that 
were once silent and clinically irrelevant have come under the spotlight as a 
potentially debilitating and lethal complication. Therefore, there is an urgent need for 
novel, affordable antiretrovirals with decreased toxicity and increased specificity, 
which are directed at sites already targeted by the current drugs, but also novel sites.  
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Figure 1.3. Schematic representation of possible and current drug-targeting sites during the 
various stages of the virus life cycle, from entry to virion maturation (Pomerantz and Horn, 
2003). 
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1.4 – HIV neutralizing aptamers as tools for  HIV research and therapy 
 
1.4.1 – Aptamers and the SELEX process 
 
Aptamers are oligonucleotides ligands that are selected for high-affinity and 
specificity for binding to molecular targets that rival those of monoclonal antibodies. 
They are selected using an in vitro process in a process called Systematic Evolution of 
Ligands by Exponential Enrichment (SELEX), (Figure 1.4) from massively complex 
combinatorial libraries (Ellington and Szostak, 1990; Robertson and Joyce, 1990; 
Tuerk and Gold, 1990).  
 
Using the SELEX protocol, aptamers with therapeutic potential have been raised 
against a wide variety of targets, from small human molecules to autoantibodies, viral 
proteins and even whole organisms (Lee, Stovall, and Ellington, 2006). Pegaptanib 
sodium, marketed under the brand name Macugen
®
 and developed by OSI 
Pharmaceuticals, was the first aptamer with a therapeutic application, used for the 
treatment of neovascular age-related macular degeneration (EYE001, 2002; EYE001: 
phase II study, 2003).  
 
Aptamers are poorly immunogenic (2003), non-toxic in therapeutic applications 
(2003; Lopes de Campos et al., 2009) and can be post-transcriptionally modified to 
increase their stability under physiological conditions (Chelliserrykattil and Ellington, 
2004; Pagratis et al., 1997). Their small size when compared to antibodies (Figure 
1.5), allows access to sites that are obscured and only transiently exposed, such as the 
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conserved region in gp120 crucial for virus entry. Another advantage of aptamers over 
antibodies is that they are made in vitro and can be re-folded if denatured. All these 
properties, coupled with their high affinity and specificity for their cognitive target 
(Green et al., 1995; Jellinek et al., 1995; Jellinek et al., 1993), make aptamers 
attractive therapeutic agents. 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Figure 1.4. Diagrammatic representation of the SELEX process. Starting with a DNA library 
containing 10
15
 randomised sequences, the resulting RNA is incubated with the ligand of 
interest and the resulting, enriched ligand-bound RNA is amplified and reverse transcribed 
into DNA. The process is repeated 10 to 20 times on average until a highly enriched 
population of aptamers with strong binding affinity is obtained from which those with the 
highest affinity and specificity are selected (Tuerk and Gold, 1990). 
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Figure 1.5. Space-filling models of an estimated comparison between a human IgG antibody 
and an anti-thrombin aptamer (Lee, Stovall, and Ellington, 2006). 
 
1.4.2 – HIV-1 neutralizing aptamers as drug candidates against AIDS 
pathogenesis and HIVCM 
 
Antiviral aptamers have been raised against several clinically important viruses 
(Gopinath, 2007): HIV (Held et al., 2006), Human Hepatitis C Virus (Kikuchi et al., 
2009; Konno et al., 2008; Nishikawa et al., 2004), and Influenza (Jeon et al., 2004; 
Misono and Kumar, 2005) to name a few. The core of our study revolves around the 
work carried out by Khati et al., 2003, Dey et al., 2005 and Cohen et al., 2008 where 
a series of aptamers were raised against the gp120 viral coat protein of HIV-1 using 
surface plasmon resonance and subsequently characterized. These aptamers showed 
high affinity and specificity for gp120 and were capable of broad-range cross clade 
neutralization of HIV clinical isolates at concentrations in the low nanomolar range. 
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Structural studies to elucidate it’s mode of action as well as to reduce its size without 
affecting functionality, have focused on a single neutralizing aptamer chosen based on 
its cross-clade HIV-1 neutralizing properties. This aptamer, B40 (later chemically 
modified and coined UCLA1) was shown to bind to the CCR5 binding pocket of 
gp120 and thereby inhibit gp120-CCR5 interaction (Cohen et al., 2008; Dey et al., 
2005; Khati et al., 2003). The occlusion of this binding pocket interferes with viral 
fusion with the host cell membrane, a vital event that precedes entry. In this fashion, 
B40 effectively interferes with the viral life cycle before infection. This represents a 
milestone in HIV chemotherapy since all other ARVs in current clinical use only 
block post-entry events by targeting reverse-transcription, integration and viral 
maturation (Figure 1.2).  It is important to mention that aptamers have been raised 
against other HIV-1 proteins, namely RT (DeStefano and Nair, 2008; Kensch et al., 
2000; Li et al., 2008; Michalowski et al., 2008), REV (Symensma et al., 1996; Tuerk 
and MacDougal-Waugh, 1993), Tat (Yamamoto et al., 1995) and integrase (Allen, 
Worland, and Gold, 1995). However, these proteins take part in the virus life cycle 
post infection and thus are presented intracellularly. Although aptamers can achieve 
their correct conformation in the intracellular environment, those targeting 
extracellular proteins have been shown to have greater therapeutic value (EYE001, 
2002; EYE001, 2003; Lupold et al., 2002; Nobile et al., 1998; Rusconi et al., 2002). 
In the context of HIVCM therapy, UCLA1 would be a good drug candidate since it 
inhibits viral replication without the cardiotoxic effects of ARVs.  Of increasing 
concern in HIVCM pathogenesis is the role played by cell-free virions. The apoptotic 
potential of these virions in CM is clearly demonstrated in the results section of this 
dissertation as is the protective role played by UCLA1. Since cell-free virus is not 
targeted by ARVs, UCLA1 could prove to be of valuable therapeutic use.   
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1.4.3 – The future of aptamers in HIV therapy 
 
Therapeutic aptamers for HIV-1 infections are still in its infancy. The in vitro 
neutralization data obtained with HIV-1 neutralizing aptamers targeting the gp120 
surface envelope glycoprotein has been very encouraging, with aptamers showing 
cross-clade neutralizing activity in the low nanomolar range (Khati et al., 
2003)(Mufhandu, unpublished data). They have also shown good potential in targeted 
delivery of siRNAs-aptamer chimeras (Zhou et al., 2008; Zhou et al., 2009). In this 
scenario, B40 and other aptamer with similar properties selectively delivered a 27 mer 
siRNA targeting the tat/rev region of HIV-1 to gp120 expressing cells, which 
efficiently blocked viral replication. Therefore, there is more than one application for 
neutralizing aptamers in HIV therapeutics and their potential is yet to be fully 
explored. However, all we have to date is in vitro data and there is a very large 
knowledge gap of the effectiveness of HIV-1 neutralizing aptamers under 
physiological conditions. Having good neutralizing properties is one of many 
variables required for the therapeutic use of aptamers. For instances, there is the risk 
that these aptamers may not have favourable pharmacokinetic properties, such as 
short plasma-half life, excessive binding to serum proteins and low conformational 
stability under physiological conditions. The only robust clinical data we have so far 
comes from Pegaptanib sodium, but the conditions under which this aptamer is used 
differ from that in which HIV-1 neutralizing aptamers would be used (2002; 2003). 
Firstly, the aptamer is administered via intraocular injection to the retina. The retina 
has limited irrigation, therefore it is easier to achieve higher serum concentrations of 
the drug under localized conditions. On the other hand, neutralizing aptamers would 
need to act systemically to fight HIV-1 infection and have to be evenly distributed 
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throughout the body. Furthermore, a delivery mechanism other than the oral route 
would not be well received in the HIV/AIDS community facing the reality that there 
currently are 23 orally-delivered and highly effective antiretrovirals in clinical use (De 
Clercq, 2009). However, advances in oral delivery technologies could soon overcome 
these hurdles (Werle, Makhlof, and Takeuchi, 2009). Several groups are working on 
matrices that allow the oral administration of recombinant, functional proteins, the 
main focus being insulin, with some very promising results recently emerging (Wood, 
Stone, and Peppas, 2008). This technology could be used to deliver any gastric-labile 
compound, including aptamers. The use of aptamers as microbicidals should be 
considered with caution since 73 pre-clinical and 45 clinical trials have not 
demonstrated efficacy in preventing HIV-1 infection with several promising 
microbicidal agents  with potent in vitro activity (Cutler and Justman, 2008).  
 
The cost factor is a major point for concern as well, since HIV-1 primarily affects 
resource-starved countries and since it requires life-long therapy, it must be 
affordable. Currently, there are a large number of highly effective ARVs that are not 
used in many countries due to cost considerations (Bartlett and Shao, 2009).  
 
Aptamers do however have properties that make them attractive ARVs. The nature of 
their chemistry makes them virtually non-toxic (EYE001, 2002; EYE001, 2003; 
Lopes de Campos et al., 2009), a property that no other ARV to date can claim. 
Furthermore, high affinity ligands are much easier and quicker to select for than with 
conventional, small-molecules. The technology simply needs to be developed until it 
can and maybe will revolutionize the field of therapeutics. 
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1.5 - Objectives of this study 
 
This work had two central objectives. The first was to examine the potential cytotoxic 
and cardiotoxic effects of UCLA1 in cultured human cardiomyocytes and peripheral 
blood mononuclear cells with the goal of using UCLA1 as a therapeutic tool. Key 
cytotoxic markers were examined, namely cell death, caspase activation, monoamine 
oxidase 1 and 2 activity, Cytochrome P450 3A4 activity and mitochondrial DNA 
depletion. 
 
The second was to dissect the mechanisms through which HIV causes cardiomyocyte 
destruction in-vivo by extrapolation from a simplified ex-vivo model using tissue-
culture adapted cardiomyocytes, primary macrophages, clinical isolates of HIV-1 
subtype C and the UCLA1 aptamer.  
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Chapter Summary  
 
The long-term cytotoxicity of antiretrovirals (ARVs) is among the major causes of 
treatment failure in HIV/AIDS patients. This calls for the development of novel ARVs 
with less or no cytotoxicity. Here, we compared the cytotoxic effects of a cross-clade 
HIV-1 neutralizing aptamer called B40,  against a panel of non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs) and the entry inhibitor (EI), T20, in human 
cardiomyocytes and peripheral blood mononuclear cells (PBMCs). An initial screen 
using cell death as the end-point measurement revealed that B40 aptamer and T20 
were the only test molecules that had insignificant (0.61< P <0.92) effect on viability 
of both cell types at the maximum concentration used. PIs were the most toxic class 
(0.001< P <0.00001), followed by NNRTIs and NRTIs (0.1< P <0.00001). Further 
studies revealed that B40 and T20 did not interfere with the cellular activity of 
cytochrome P450 3A4 enzyme (0.78< P <0.24) or monoamine oxidase (MAO) A and 
B (0.83< P <0.56) when compared to untreated controls of both cell types. 
Mitochondrial-initiated cellular toxicity is closely associated with use of ARVs. 
Therefore we used real-time PCR to quantify the relative ratio of mitochondrial to 
nuclear DNA as a marker of toxicity. The levels of mitochondrial DNA when 
compared to untreated controls, remained unchanged in cells exposed to B40 aptamer 
(0.5> P >0.06). These data support the development of B40 and related EI aptamers 
as new ARVs with no cytotoxicity at the estimated potential therapeutic dose. 
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1.0 – Introduction 
 
The introduction of highly active antiretroviral therapy (HAART) has significantly 
reduced morbidity and mortality in HIV/AIDS patients. This however requires life-
long treatment and results in toxicity in up to 50% of patients following 6-12 months 
of therapy (Bongiovanni et al., 2005; Mocroft et al., 1998). Treatment failure arising 
from toxicity has highlighted the need for close medical supervision and, ultimately, 
the development of novel, less toxic ARVs. This is of even greater concern in the 
resource-poor African continent where, unlike in developed countries, monitoring, 
diagnosis and management of ARV-associated toxicity is not routinely conducted 
(Mutimura et al., 2008). This problem is likely to increase as use of ARVs becomes 
more widespread in resource-poor settings (Beck et al., 2006).  
 
Mitochondrial toxicity is one of the major complications associated with long term 
use of HAART (Brinkman, 2001; Brinkman and Kakuda, 2000; Kakuda, 2000; 
Kakuda et al., 1999; Walker and Brinkman, 2001a; Walker and Brinkman, 2001b).  
NRTIs used in HAART inhibit DNA polymerase γ, which is solely responsible for 
mitochondrial DNA (mtDNA) replication (Lewis and Dalakas, 1995).  Through this 
mechanism, NRTIs induce depletion of mtDNA as well as mtDNA-encoded enzymes 
(Brinkman et al., 1999).  This results in mitochondrial dysfunction and eventually 
leads to a range of complications such as bone marrow suppression and 
cardiomyopathy (DiMauro and Schon, 2003).  
 
In addition to mitochondrial toxicity, other markers of cytotoxicity caused by ARVs 
are cell death, modulation of cytochrome P450 (CYP450) and monoamine oxidase 
MAO A and B enzymes.  CYP450 enzymes are mostly amine oxidases and key 
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metabolizers with regard to catalytic versatility and the broad spectrum of oxidative 
transformation of both exogenous and endogenous molecules (Guengerich, 2001). 
This enzyme superfamily plays a vital role in tissue and cardiovascular health 
(Elbekai and El-Kadi, 2006)   On the other hand, MAO enzymes are flavoenzymes 
that catalyse the oxidative deamination of a large number of biogenic and xenobiotic 
amines (Edmondson et al., 2004; Kalgutkar et al., 2001). Therefore any drug that 
interacts with MAO, regardless of its function, can lead to a decrease in normal MAO 
cellular activity. This in turn can result in a potentially lethal intracellular 
accumulation in the levels of its natural substrates such as serotonin (Dams et al., 
2001).  
 
For reasons of toxicity associated with use of ARVs,  here we studied the cytotoxic 
effects of one of the potent and cross-clade HIV-1 neutralizing RNA aptamers called 
B40, which was recently isolated and described (Cohen et al., 2008; Dey et al., 2005b; 
Khati et al., 2003).  B40 aptamer blocks viral entry by binding to core conserved 
residues on gp120 at the heart of the CCR5 binding site (Cohen et al., 2008; Dey et 
al., 2005a). While this is the first study that describes the in vitro toxicity of the 
experimental HIV-1 gp120 binding RNA aptamer, previous studies have shown that 
the vascular endothelial growth factor (VEGF) binding aptamer did not have any 
intrinsic toxicity in preclinical assessment (2002; Drolet et al., 2000). Single dose and 
repeated dosing toxicity studies with anti-VEGF aptamer conducted in rats, rabbits, 
and Rhesus monkeys showed that there was no-observable-adverse-effect-level 
(NOAEL) or dose limiting toxicity (2002; 2003; Drolet et al., 2000).     
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In this study, we evaluated toxicity of anti-gp120 aptamer called B40 using cell 
viability, CYP450 3A4 (CYP3A4), MAO A and B and mtDNA levels as markers of 
cytotoxicity in human cardiomyocytes and PBMCs. Toxicity was evaluated in human 
cardiomyocytes due to the association of cardiomyopathy with use of ARVs 
(Herskowitz et al., 1992; Lewis, Simpson, and Meyer, 1994) and PBMCs because 
CD4
+
 T-cells and macrophages found in PBMCs are the backbone of the immune 
system.  HIV-1 predominantly infects and replicates in these cells.  
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2.0 - Materials and methods 
 
 2.1 – ARVs 
 
All ARVs were obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH, USA. Four classes of ARVs were tested in 
this study. NNRTIs: Nevirapine (NVP) and Efavirenz (EFV); NRTIs: Abacavir 
(ABC), Dideoxycytidine (ddC), Zidovudine (AZT), Stavudine (d4T), Tenofovir 
(TDF) and Lamivudine (3TC); PIs: Saquinavir (SQV), Ritonavir (RTV), Nelfinavir 
(NFV), Lopinavir (LPV), Tipranavir (TPV), Indinavir (IDV), Amprenavir (APV) and 
Darunavir (DRV) and  the Entry Inhibitor (EI): Enfuvirtide (T20).  
2.2 - In vitro transcription and validation of monoclonal aptamers 
 
Plasmid DNA containing the B40 aptamer was amplified by PCR as previously 
described (Khati et al., 2003). The PCR product was purified using the Wizard
®
 SV 
Gel and PCR Clean-Up System (Promega, USA) and in vitro transcribed to RNA 
using 2′-fluoro-pyrimidines (TriLink, USA) as previously described (Khati et al., 
2003). The resulting 2'-F-RNA aptamer was quantified using the NanoDrop
®
 ND-100 
spectrophotometer (Thermo Fisher Scientific, USA). Prior to use the RNA aptamer 
was refolded by heating in water to 95°C for 5 minutes and then cooling to room 
temperature for 5 minutes. This was followed by the addition of 1/20 volume of 20× 
refolding buffer (final concentration:10mM HEPES pH 7.4; 150mM NaCl; 1mM 
CaCl2; 1mM MgCl2; 2.7mM KCl) and incubated at room temperature for an 
additional 10 minutes. The refolded aptamer was validated by binding to recombinant 
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gp120 derived from HIV-1Ba-L using BIAcore

 3000 (GE Healthcare, USA) as 
previously described (Khati et al., 2003).  
2.3 - Recombinant HIV-1Ba-L gp120 
 
HIV-1Ba-L gp120 was obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH. 
2.4 - Culture and phenotyping of human cord-blood stem cell-derived 
cardiomyocytes 
 
The human cord-blood stem cell-derived cardiomyocytes were purchased from 
Celprogen (California, USA). The cardiomyocytes were cultured in Human 
Cardiomyocyte Expansion Media (a proprietary media containing, serum, growth 
factors and antibiotics) and in tissue culture flasks containing a proprietary growth 
matrix at 37°C, 5% CO2. The media and flasks were also purchased from Celprogen, 
USA.  
 
The cardiomyocytes were phenotyped by immunocytochemistry using a cardiac 
specific monoclonal antibody that targets the first 32 amino acids of the c-terminus of 
the human cardiac protein troponin I (R&D Biosystems, USA) and detected using an 
anti-goat Rhodamine labelled antibody produced in chickens (Santa Cruz, USA). 
Briefly, a cell monolayer growing on a chamber slide (Lab-Tek, Nunc, USA) were 
fixed and permeabilized in 2% PFA and 0.1 % Triton X-100 (Sigma, Germany) for 30 
min. Following this, primary antibody was added at a concentration of 10 g/ml in the 
presence of 1% normal goat serum (Invitrogen, USA) and incubated for 1 hour on ice. 
The cells were then washed 4 times with ice-cold PBS prior to the addition of the anti-
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goat rhodamine-conjugated secondary antibody, at a concentration of 5 g/ml. 
Following incubation for 1 hour, the cardiomyocytes monolayer was covered with a 
glass coverslip in the presence of Mounting Medium (UltraCruz,Santa Cruz 
Biotechnology, USA) for immunofluorescence analysis.  
2.5 - Isolation and cultivation of human peripheral blood mononuclear cells 
(PBMCs) 
 
PBMCs were isolated from heparinised human buffy coats of normal, HIV-negative 
donors as previously described (Khati et al., 2003). Buffy coats were obtained from 
the South African National Blood Services. Briefly, buffy coats were layered into 
Ficoll-Paque™ PLUS (GE Healthcare, USA) and PBMCs isolated by density-gradient 
centrifugation. Following a 2000 rpm centrifugation for 30 min at 20 ºC, the PBMC 
layer was harvested and washed once with ice cold PBS (Lonza, USA). The cell pellet 
was then suspended in 30 ml of a hypotonic solution of ice-cold ammonium chloride 
and incubated at room-temperature for 20 min to lyse the remaining red-blood 
corpuscles. The cells were harvested by centrifugation and seeded on tissue culture 
flasks (Corning, USA) at a density of 2×10
6
 cells/ml in RPMI medium containing 
20% fetal bovine serum (Sigma-Aldrich, Germany), followed by PHA stimulation and 
IL-2 treatment as previously described (Khati et al., 2003). For comparison we also 
cultured PBMCs without mitogen (PHA) and without IL-2 in X-VIVO-10 media 
(BioWhittaker) supplemented with 2% autologous serum because we previously 
showed that this system produces a slowly proliferating mixed culture of CD4
+
 T 
lymphocytes and macrophages that supports a higher level of replication of HIV-1 
primary isolates (Khati et al., 2003).  
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2.6 - Cell viability assay 
 
PHA stimulated, IL-2 treated PBMCs and cardiomyocytes in the log-phase growth 
were seeded at a density of 20,000 cells/well in 96-well white opaque wall, tissue 
culture plates (Nunc™, Thermo Fisher Scientific, USA) in a volume of 100 μl growth 
media. Unstimulated PBMCs cultured in X-VIVO-10 media (BioWhittaker, USA) 
supplemented with 2% autologous were also seeded as above.  The overlay media in 
either system was replaced with the relevant culture media containing the drug at a 
concentration equivalent to the maximum plasma concentration in patients at a pre-
determined therapeutic dose (Cmax) or an equivalent amount of the aptamer (Table 1). 
Following 24 hour incubation, the overlay media was removed and replaced with 
fresh media. The overlay media was replaced every 2 days for the duration of the 
experiment. The assay was done in triplicates and independently repeated twice. 
Following 7 days of incubation the cell viability was determined using the ATP-based 
assay CellTiter-Glo
®
 Luminescent Cell Viability Assay (Promega, USA). Both the 
plates and the reagent were allowed to equilibrate at room temperature. Then an equal 
volume of reagent was added to the wells and further incubated at room temperature 
for 20 minutes to allow for the luminescent signal to stabilize. Following the 
incubation, the luminescent signal was measured in a Modulus
®
 Microplate Reader 
luminometer (Promega, USA) using a count integration time of 1 second. The raw 
data was measured in relative light units (Merluzzi et al.) and the final results were 
normalized (i.e. the total number of viable cells in the treated samples were 
respectively subtracted by the total number of viable cells in the cell control–which 
was not treated with any drug or test molecule) and expressed as percentage cell 
death. The cell controls, which were not treated, were on average more than 95% 
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viable. Wells containing media alone were used as controls for background 
luminescence and subtracted from the test values. DMSO at a concentration of 0.1% 
(v/v) was used as a solvent for most ARVs; hence a control for DMSO-initiated 
toxicity was included whereby cells were treated with 0.1 % DMSO for the duration 
of the study. The general formula to calculate percentage toxicity was: % of viable 
cells = [(RLU of drug treated cells - RLU of medium control) ÷ (RLU of untreated 
cell controls - RLU of medium control)] × 100.  The % of dead cells = 100% - % of 
viable cells.  
2.7 - Caspase 3/7 activity 
 
Representatives from each class of ARVs were selected for apoptosis screening in 
cardiomyocytes and PBMCs, namely: EFZ (NNRTI), ABC and TDF (NRTI), RTV 
and IND (PIs), T20 and B40 aptamer (EI). Cells were seeded at a density of 50,000 
cells/well in 24- well tissue culture plates (Corning, USA) and incubated with ARVs 
at the Cmax for 1 and 7 days respectively. After each time point elapsed the cells were 
immediately frozen at -80 ºC. Day 7 cells were frozen for 24 h prior to assay. The 
cells were then equilibrated to room temperature and an equal volume of Caspase-Glo 
3/7
®
 detection reagent was added (Promega, USA). Following 2 h of incubation the 
resulting luminescent signal was measured in a Modulus
®
 Microplate Reader 
luminometer (Promega, USA) using a count integration time of 1 second. The results 
were expressed as relative light units, blank subtracted (RLU, blank subtracted) 
against ARVs on the x-axis. 
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2.8 - Monoamine oxidase A & B enzyme activity assay 
 
This assay was carried out using the MAO-Glo™ Assay kit (Promega, USA).  A 96-
well white opaque wall, tissue culture plate was seeded with either cardiomyocytes or 
PBMCs and incubated in triplicate with the test ARV or aptamer at a maximum 
starting concentration of 2 μM followed by ½ log serial dilutions. The overlay media 
was removed and the cell monolayer was washed with PBS (Lonza, USA) and lysed 
with 50 μl proprietary lysis buffer (Promega, USA). The cell debris was removed by 
centrifugation at 2000 rpm and the supernatant was recovered and incubated with 
MAO A or B enzyme substrate for 3 hours at room temperature. This was followed by 
the addition of the detection reagent. After 1 hour of incubation the luminescent signal 
was measured in a Modulus
®
 Microplate reader (Promega, USA) luminometer using a 
count integration time of 1 second. The raw data was measured in RLU and the final 
results were normalized as in the cell viability assay above and expressed as a 
percentage of enzyme activity. A no-substrate control sample was included as control 
for background luminescence and subtracted from the test values. Clorgyline (Sigma-
Aldrich, Germany) was used as a positive control for MAO A inhibition and Deprenyl 
(Sigma-Aldrich, Germany) for MAO B. The general formula used to calculate 
percentage enzyme activity was: % of enzyme activity = [(RLU of drug treated cells - 
RLU of medium control) ÷ (RLU of untreated cell controls - RLU of medium 
control)] × 100.   
2.9 - Cytochrome P450 3A4 activity 
 
The P450 Glo™ Assay kit was used (Promega, USA). Cells were seeded as described 
above in the presence of the aptamer or ARVs and incubated for 2 days. The overlay 
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media was then removed and 60 μl of fresh media was added which contained 50 μM 
of the luciferin substrate. After 4 hours of incubation, 50 μl culture supernatant from 
each well was transferred to a 96-well white opaque wall, tissue culture plates 
(Nunc™, Thermo Fisher Scientific, USA) and an equal volume of detection reagent 
was added. The luminescent signal was measured after 1 minute of incubation, in a 
Modulus
®
 Microplate reader (Promega, USA) luminometer as described above. A no-
substrate control sample was included as control for background luminescence and 
subtracted from the test values. The protease inhibitor Ritonavir was used as a 
positive control for CYP3A4 inhibition. Cell culture supernatant from untreated cells 
was used as the baseline for CYP4503A4 activity.  
2.10 - Real-time PCR for quantification of mitochondrial DNA toxicity 
 
Cells were exposed to the B40 aptamer, T20 or ddC at 2 µM for 7 days. Following 
exposure to the test molecule for 7 days, the cell monolayer was washed with warm 
PBS and the cells were lysed in 50 μl lysis buffer (Promega, USA), which was 
compatible with the PCR mix. A volume of 2 μl lysate was subjected to PCR for both 
genomic and mitochondrial DNA in a LightCycler® (Roche, Switzerland). The target 
nuclear gene was the human polymerase γ accessory subunit (ASPOLG) and the 
mitochondrial gene was cytochrome-c oxidase I (CCOI). For ASPOLG the forward 
primer 5′ GAC CTG TTG ACG GAA AGG AG 3' and the reverse primer 3' CAG 
AAG AGA ATC CCG GCT AAG 5' were used for PCR amplification. The CCOI 
primer pair consisted of the forward primer sequence 5' TTC GCC GAC CGT TGA 
CTA TT 3' and reverse primer 3' AAG ATT ATT ACA AAT GCA TGG GC 5'. PCR 
reactions were carried out with the master mix Power SYBR
®
 Green 5 (Applied 
Biosystems, USA) in the presence of 5 mM MgCl2 (Promega, USA). Cycling 
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conditions consisted of a single enzyme-activation step of 10 min at 95 ºC, followed 
by 45 cycles of denaturing at 95 ºC for 0 s, annealing at 60 ºC for 10 s, elongation at 
72 ºC for 5 s with a temperature transition rate of 20 ºC/s. The relative amount of 
mitochondrial and nuclear DNA was extrapolated from a standard curve and the 
results were calculated as the mean ratio of mitochondrial to nuclear DNA. Each 
experiment was carried out in triplicate and the results represent the average between 
two independent experiments. The mtDNA:nDNA ratio of the untreated controls was 
arbitrarily set at 1.0 and was used as the baseline measurement.  
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TABLE 1: Maximum blood plasma concentration (Cmax) in patients and in vitro data 
of ARVs    
   
ARVs Cmax(µM)
a 
In vitro data 
Class   Cell
b Strainc IC50(µM)
d TIe Reference 
NNRTI
s 
NEV 16.9 C816
6 
IIIB 0.04 8000 (Merluzzi et 
al., 1990) 
EFV 15.7 PBM
C 
Primary 
isolates 
IC95=0.0015-
0.003* 
>5000
0 
(Young et 
al., 1995) 
 
NRTIs 
ABC 14.7 PBL IIIB 4 40 (Melroy and 
Nair, 2005) 
ddC 0.12 PBM
C 
LAV 0.011 >9000 (Chu et al., 
1988) 
AZT 48.8 PBM
C 
IIIB 0.05 1000 (Mitsuya et 
al., 1985) 
D4T 5.3 PBM
C 
LAV 0.009 7778 (Chu et al., 
1988) 
TDF 1.0 MT-2 IIIB 0.003 16667 (Robbins et 
al., 1998) 
3TC 8.8 CEM RF 0.18 >2000 (Coates et 
al., 1992) 
 
 
PIs 
SQV 3.7 C816
6 
RF 0.0002 >5000
0 
(Roberts et 
al., 1990) 
RTV 21.0 PBL Primary 
isolates 
0.045 1089 (Kempf et 
al., 1995) 
NFV 7.0 MT-2 RF 0.043 651 (Patick et 
al., 1996) 
LPV 15.7 MT-4 NL4-3 0.005 >2000
0 
(Carrillo et 
al., 1998) 
TPV 0.2 MT-4 NL4-3 0.016 >2000 (De Meyer 
et al., 2005) 
IND 15.4 MT-4 IIB IC95=0.1* >4000 (Vacca et 
al., 1994) 
AM
P 
15.1 MT-4 IIIB 0.054 >1600 (Baba et al., 
1997) 
DR
V 
13.6 MT-2 LAI 0.003 24667 (Koh et al., 
2003) 
EIs T20 1.0 PBM
C 
LAI  - (Wild et al., 
1994) 
B40
f - PBM
C 
Primary 
isolates 
IC50<0.01, 
IC95<0.1*  
>5000 (Cohen et 
al., 2008; 
Dey et al., 
2005b; 
Khati et al., 
2003) 
                                                                                                                                                
aThe Cmax of all registered ARVs were taken from package inserts of the respective 
drugs.  
b
Cell type used to obtain respective in vitro data 
c
Strain of HIV-1 used to obtain respective in vitro data 
d
IC50 (inhibitory concentration) is the effective concentration of the drug that inhibits 
HIV-1 in infected cells by 50%  
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*IC95 is the concentration of drug that inhibits HIV-1 in infected cells by 95%. 
e
TI (Therapeutic Index) is the relation between the CC50 (inhibitory concentration that 
reduces cellular growth or viability of uninfected cells by 50%, data not shown) and 
IC50 and it is obtained using the general formula: TI = CC50/IC50 
f
B40 aptamer is an experimental anti-HIV-1 molecule and not yet registered for 
clinical use. For this reason its Cmax in blood plasma of patient has not been 
established. It was used at 2 µM, which is twice the Cmax of T20 and more than 200-
fold its IC50. The CC50 of B40 could not be obtained even after using the aptamer at 
50 µM, which had similar effect as 2 µM. 
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3.0 – Results 
 
3.1 - Effect of B40 aptamer in comparison to ARVs on viability of human 
PBMCs and cardiomyocytes  
 
We evaluated toxicity of a novel gp120-binding and HIV-1 neutralising RNA aptamer 
called B40, in comparison to conventional ARVs, in human cord-blood stem cell-
derived cardiomyocytes (Figure 1) and in human PBMCs. The strong staining for 
cTnI positively identified the phenotype of these poorly-reported cells as being human 
cardiomyocytes (Figure 1C and D). An initial screen using an ATP cell-based assay 
to measure cell death as the end point measurement of cell toxicity showed that B40 
aptamer, which is a novel EI, did not cause death of either human cardiomyocytes 
(1±0%; P = 0.74) or PBMCs (0±5%; P = 0.92) at a maximum concentration of 2 µM 
used (Figure 2). The maximum concentration of 2 M used for B40 in this study is 
more than 200-fold the B40 concentration (<10 nM) required to inhibit 50% (IC50) of 
HIV-1 in PBMCs (Cohen et al., 2008; Dey et al., 2005b; Khati et al., 2003).  The 
property of the B40 aptamer to cause no cell death at the maximum concentration 
used compared favourably to the registered EI called T20, which also did not cause 
cell death in cardiomyocytes (1±3%; P = 0.74) and PBMCs (0±6%; P = 0.61). All 
other classes of ARVs tested caused significant cell death in either or both 
cardiomyocytes and PBMCs (Figure 2). PIs were generally the most toxic class of 
ARVs in both cardiomyocytes and PBMCs causing up to almost 100% (0.0002< P 
<0.00001) cell death at the maximum concentration used (Figure 2). The two 
NNRTIs tested, NEV and EFV, respectively caused 80% (0.1< P <0.002) and 60% 
(0.1< P <0.002) cell death in PBMCs, while they both caused about 20% (0.004< P 
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<0.002) cell death in cardiomyocytes (Figure 2). NRTIs were generally the second 
least toxic class of ARVs after EIs, causing less than 20% cell death in 
cardiomyocytes and between 20% and 72% toxicity in PBMCs (Figure 2). 
 
 
 
Figure 1: Phenotyping of human cord-blood stem-cell derived cardiomyocytes. 
Cardiomyocytes were cultured in chamber slides, permeabilized and treated with (A) 
rhodamine-labelled secondary antibody only to exclude non-specific binding (B) 
DAPI nuclear stain; (C) cTnI primary and rhodamine-labelled secondary antibody (D) 
a composite image was created by superimposing images B and C. 
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Figure 2:  Effect of B40 aptamer in comparison to a panel of 17 ARVs on viability of 
human cardiomyocytes and PBMCs. Human cord-blood stem cell-derived 
cardiomyocytes or freshly isolated PBMCs were seeded at a density of 20 000 
cells/well in 96 well plates and exposed to respective ARVs at a concentration 
equivalent to the maximum blood plasma concentration (Cmax) shown in Table 1 or 
the B40 aptamer at 2 µM. All experiments were done in triplicates and independently 
repeated twice. ATP levels were measured as a correlate of cell viability after 7 days 
of exposure by relating the RLU of treated to untreated cells. The results were 
normalised and expressed as percentage cell death in the treated samples as compared 
to untreated cells. Data on the graph shows the mean and standard deviation bars of 
three replicates in two sets of independent experiments. ARVs whose toxicity was 
statistically difference from that of the untreated controls as determined by the t-test 
are indicated by asterisks, where, *, **, *** indicate P values of less than 0.01, 0.001 
and 0, 0001 respectively.  
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3.2 - Cell death was caspase independent 
 
 
We probed further into the mechanism through which ARVs were inducing cell death 
by measuring the activity of two executioner caspases, caspase 3 and 7 respectively. 
In spite of robust cell death induced by most ARVs in this study (Figure 2), no 
increase in caspase activity was observed in all ARVs tested, when compared to 
untreated control cells (Figure 3 A and B). A sharp and statistically significant 
decrease in caspase activity was observed at day 1 for ABC, RTV and IND treated 
PBMCs only and days 4 and 7 in both cell types treated with EFV, ABC, TDF (day 7 
in PBMCs only), RTV and IND treatments, which directly correlated with the 
observed decrease in cell viability (Figure 2). T20 and B40 treated cells were the only 
cells that had no significant changes in caspase activity levels at the measured time 
points. 
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Figure 3: Caspase 3/7 activation upon ARV exposure. Cells seeded at a density of 
50,000 cells/well were exposed to EFZ, ABC, TDF, RTV, IND, T20 and B40 aptamer 
at the Cmax for 1 and 7 days respectively. No statistically significant increases were 
observed for any ARV, including the B40 aptamer in either cardiomyocytes (A) or 
PBMCs (B) when compared to the untreated controls. A statistically significant 
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decrease in caspase activity was observed in day 1 in PBMCs only for ABC, RTV and 
IND treated cells; at day 4 and 7 for EFV, ABC, TDF (day 7 only in PBMCs), RTV 
and IND treated cells. The asterisks * and ** denote P values of less then 0.002 and 
0.0002 respectively. The data was presented in bar graphs relating RLUs to ARVs and 
shows the mean and error bars of three replicates. 
 
3.3 - B40 aptamers did not affect levels of MAO enzymes A and B  
 
Since the B40 aptamer and T20 (both EIs) were the only test molecules that had no 
effect on cell viability and caused insignificant cell death–an end point marker of 
cytotoxicity; we selected them for more in-depth cytotoxic analysis at the enzyme and 
cell metabolism level.  We measured the interaction of B40 aptamer with MAO A and 
B enzymes, because any drug that interacts with MAO A or B, regardless of its 
function, can lead to a decrease in normal MAO cellular activity. This in turn can 
result in a potentially lethal intracellular accumulation in the levels of its natural 
substrates such as serotonin. It is therefore important to screen potential drugs for 
possible interaction with MAO enzymes. In this study, we measured the levels of both 
MAO A and B enzymes in the presence of B40 aptamer and for comparison, T20. The 
results clearly indicated that neither of the MAO isozyme was inhibited or induced by 
B40 aptamer or T20 in both cardiomyocytes and PBMCs as compared to untreated 
control cells (Figure 4A-D). However, MAO A was inhibited in a concentration-
dependent manner by clorgyline (Figure 4A and B) and MAO B in a similar manner 
by deprenyl (Figure 4B and D). Clorgyline and deprenyl, which were used as 
inhibitors of MAO A and MAO B respectively, served as good controls and 
confirmed the presence and activity of both isozymes in cardiomyocytes and PBMCs, 
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and that these isozymes were amenable to interference by certain drugs or specific 
inhibitors.   
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Figure 4: MAO A and B enzyme modulation by B40 aptamer and T20 in 
cardiomyocytes (A, C) and PBMCs (B, D).  Cells were incubated in triplicates with a 
serially diluted test molecule at a maximum concentration of 2 µM for 2 hours. A cell 
lysate was incubated with MAO A or B substrate for 1 hour followed by the addition 
of detection reagent and the resulting luminescence signal was quantified in a 
luminometer. The no-treatment control was used as the baseline for maximum 
enzyme activity. No change in enzyme activity was detected for both MAO A and B 
in the presence of B40 aptamer and T20 for both cardiomyocytes and PBMCs. 
However, there was a dose-dependent inhibition of MAO A by clorgyline and MAO 
B by deprenyl, which are respectively well documented inhibitors of MAO A and 
MAO B indicating the presence and activity of both enzymes in human 
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cardiomyocytes and PBMCs. Enzyme activity was calculated by relating the RLUs of 
untreated control cells to that of the treated cells as a percentage. Data on the graphs 
represent the mean and error bars of three replicates in two sets of independent 
experiments.   
3.4 - B40 aptamer did not affect the level of CYP450 3A4 enzyme  
 
Cytochrome P450 3A4 is another key enzyme involved in cell metabolism and 
commonly affected by the PI class of ARVs.  For this reason, we tested if B40 
aptamer modulates this enzyme in human cardiomyocytes and PBMCs.  B40 aptamer 
favourably compared to T20 and did not significantly affect the level of CYP3A4 
compared to untreated negative controls in both cardiomyocytes (P = 0.78 for T20 
and P = 0.37 for B40 aptamer) and PBMC (P = 0.62 for T20 and P = 0.24 for B40 
aptamer) even at the highest concentration used (Figure 5A and B).  However, as a 
positive control, CYP3A4 was significantly inhibited in a concentration-dependent 
manner by the protease inhibitor Ritonavir in human cardiomyocytes (P = 0.0001) 
and PBMCs (P = 0.0008). 
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Figure 5: Effect of B40 aptamer and T20 in CYP3A4 enzyme activity in 
cardiomyocytes (A) and PBMCs (B). Cells were seeded at a density of 20 000 
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cells/well and exposed to the respective test molecule in triplicate for 2 days at 
serially diluted concentrations. The overlay media was removed and fresh media was 
added containing a luciferin luminogenic substrate for CYP3A4 enzyme. After four 
hours of incubation the luciferin detection reagent was added and the resulting 
luminescence signal was quantified in a luminometer. The no-treatment control was 
used as the baseline for maximum enzyme activity and Ritonavir, a known inhibitor 
of CYP3A4 (Ikezoe et al., 2004; Patel et al., 2004), as a positive control.  Data on the 
graphs represent the mean and error bars of three replicates in two sets of independent 
experiments. 
3.5 - B40 aptamer did not cause mitochondrial DNA toxicity 
 
Mitochondrial toxicity is one of the major complications associated with long term 
use of ARVs, specifically NRTIs. To complete the circle, we further tested if B40 
aptamer will cause mitochondrial DNA depletion in human cardiomyocytes or 
PBMC.   Similar to T20, the B40 aptamer did not cause a significant decrease in the 
mtDNA levels when compared to the untreated control in both cardiomyocytes and 
PBMCs (Figure 6). The mtDNA: nDNA for B40 aptamer in cardiomyocytes was 
1.17±0.19, P = 0.3 and in PBMCs was 1.16±0.11, P = 0.06, while that for T20 in 
cardiomyocytes was 1.01±0.17, P = 0.5 and for PBMCs was 1.08±0.10, P = 0.3.  The 
NRTI ddC was used as a positive control for mtDNA depletion and resulted in an 
mtDNA: nDNA ratio of 0.72±0.12, P = 0.006 in cardiomyocytes and 0.41±0.18, P = 
0.0004 in PBMCs (Figure 6).   
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Figure 6: Effect of B40 aptamer and T20 on mitochondrial toxicity as measured by 
mtDNA:nDNA ratio in cardiomyocytes and PBMCs. Cardiomyocytes and PBMCs 
were respectively exposed to 2 μM of B40 aptamer, T20 or ddC in triplicates for 7 
days. Relative amounts of nuclear and mitochondrial DNA were quantified by real 
time quantitative PCR amplification of the CCOI nuclear and the ASPOLG 
mitochondrial genes respectively. The data was extrapolated from a standard curve 
relating cycle numbers to relative DNA concentration. The mtDNA:nDNA ratio of 
untreated sample was arbitrarily set at 1.0. Only the ddC treated cells showed a 
statistically significant decrease in mtDNA:nDNA ratio compared to untreated control 
as determined by a t-test and indicated by asterisk, where * and ** indicate p values of 
less than 0.001 and 0.0001 respectively.  Data on the graph represent the mean and 
error bars of three replicates in two independent experiments.     
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4.0 - Discussion 
 
This study describes the cytotoxic effects of a novel, cross-clade HIV-1 neutralising 
RNA aptamer called B40 in comparison to conventional ARVs.  We used cell death, 
caspase 3/7 activation, MAO A and B, CYP450 3A4 and mitochondrial DNA levels 
as markers of toxicity in human cardiomyocytes and PBMCs.  First, in contrast to 
most registered ARVs tested, the B40 aptamer did not cause death of cardiomyocytes 
and PBMCs even at the highest concentration tested of 2 µM. This is encouraging, 
particularly because the IC50 of HIV-1Ba-L  and several HIV-1 primary isolates by the 
B40 aptamer in PBMCs is less than 10 nM (Cohen et al., 2008; Dey et al., 2005b; 
Khati et al., 2003).  We have also observed that cell death is independent from 
caspase 3 and 7 activation. These are executioner caspases that are involved in all 
caspase-mediated apoptotic pathways (Chowdhury, Tharakan, and Bhat, 2008) and 
our data clearly demonstrated that NRTI and NNRTIs induced apoptosis is caspase 
independent. These observations are in general agreement with the literature where 
cell death was frequently reported as being the result of mitochondrial injury (Kohler 
and Lewis, 2007). Mitochondrial toxicity is one of the major side effects and causes 
of treatment failures associated with mid to long-term use of ARVs, especially NRTIs 
(Kohler and Lewis, 2007).  The severity of mitochondrial toxicity can range from 
clinically silent to life-threatening conditions such as lactic acidosis (Carr et al., 
1998b). One of the most accepted hypotheses of mitochondrial toxicity is that ARVs 
cause a depletion of mitochondrial DNA due to inhibition of the mitochondrial DNA 
polymerase γ (Lewis and Dalakas, 1995; Lewis, Day, and Copeland, 2003). This 
results in impaired production of mitochondrial enzymes, which participate in 
oxidative phosphorylation, ultimately leading to diverse organ-specific and/or 
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systemic pathological changes. It was for this reason that we examined the B40 
aptamer for mitochondrial toxicity and we have unequivocally shown that B40 does 
not interfere with mitochondrial DNA synthesis, ruling out potentially deleterious 
mitochondrial interactions associated with the therapeutic use of this compound, via 
the known pathways of ARV-induced mitochondrial toxicity. Due to the high 
incidence of these cases, the NRTI ddC is used with extreme caution in the clinical 
setting. Furthermore, PI-related toxicity was also caspase-independent as cell-death 
was not preceded by an increase in caspase-3 and -7 activity and the sharp decrease in 
caspase activity for most ARVs (Figure 3) was the result of a decrease in the total 
number of viable cells (Figure 2). The exact mechanism by which PIs induce cell 
death have not been fully dissected (Badley, 2005), but cell cultures treated with 
Ritonavir showed an accumulation of growth-arrested cells in the G1 phase and high 
levels of expression of the universal cyclin-Cdk kinase inhibitor p21 (Gaedicke et al., 
2002). It has been speculated that accumulation of p21 could be due to inhibition of 
cellular proteosome resulting in cell death (Sekiguchi and Hunter, 1998). Therefore 
necrosis due to chemical insult is the most likely cause of cell death although caspase-
independent apoptosis cannot be ruled out (Badley, 2005).   
 
Another favorable property of B40 aptamer shown in this study is that the aptamer did 
not interact with MAO A and B enzymes.  The two MAO isoforms are present in 
most tissues, including peripheral tissues and the myocardium (Grimsby et al., 1990; 
O'Carroll et al., 1989; Rodriguez et al., 2000; Saura et al., 1996; Shih, Grimsby, and 
Chen, 1990; Thorpe et al., 1987). Drugs interacting with MAO A or B can cause 
either up-regulation or down-regulation of the enzymes, leading to concomitant 
accumulation or depletion of neurotransmitters and resulting in serious clinical 
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effects.  Clorgyline and deprenyl, which we used in this study as positive controls, are 
well documented inhibitors of MAO A (Hewton, Salem, and Irvine, 2007; Kitanaka et 
al., 2005) and MAO B (Braestrup, Andersen, and Randrup, 1975; Elsworth et al., 
1978), respectively.  No ARV in current clinical use has been shown to interact with 
either MAO A or MAO B.  Notwithstanding, given the metabolic importance of MAO 
A and MAO B and its putative interaction with other drugs, it was imperative and 
prudent to look at its potential interaction with the B40 aptamer.   
 
The B40 aptamer, favorably compared to T20, also did not affect CYP3A4 activity in 
both PBMCs and cardiomyocytes. Most ARVs, notably PIs are substrates and potent 
competitive inhibitors of CYP3A4 (Ernest, Hall, and Jones, 2005). The CYP450 
superfamily of haeme-containing enzymes is the major catalyst for the oxidative 
transformation of most therapeutic drugs and xenobiotics in general, as well as a vast 
array of endogenous substances (Kalgutkar, Obach, and Maurer, 2007). The 
interaction of ARVs with members of the CYP450 enzyme superfamily often causes 
inactivation of the enzyme leading to decreased plasma levels of protease inhibitors 
(Kalgutkar, Obach, and Maurer, 2007). This effect is often counteracted in the clinical 
setting by the co-administration of Ritonavir, which is a potent inhibitor of CYP3A4 
(Ikezoe et al., 2004; Patel et al., 2004), with other protease inhibitors (Youle, 2007). 
In this case, Ritonavir plays a dual role of both antiretroviral activity and CYP450 
3A4 enzyme inhibition to boost plasma levels of other PIs. However, this is closely 
associated with an increased incidence of both metabolic and somatic cardiac 
changes, which are often silent diseases because they are not readily diagnosed.  
Lipodystrophy, hyperlipidaemia and insulin resistance are some of the most common 
such disorders (Carr and Cooper, 2000; Carr et al., 2000; Carr et al., 1998a; Carr et 
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al., 1998b).  Furthermore, the potent inhibition of CYP3A4 by most PIs, especially 
Ritonavir (Ikezoe et al., 2004; Patel et al., 2004) seriously restricts the use of other 
auxiliary drugs that are also metabolized by the same enzyme as this could lead to 
life-threatening cardiac events such as arrhythmias.  The property of B40 aptamer to 
potently and broadly neutralize HIV-1 (Dey et al., 2005b; Khati et al., 2003) without 
inhibiting CYP3A4 therefore makes it an ideal candidate drug to complement existing 
ARVs.     
 
Taken together, these data show that B40 aptamer does not interfere with any of the 
major pathways of ARV-related cytotoxicity. These data agree with toxicological 
observations made with Pegaptanib sodium (Macugen
®
), which is the first and only 
aptamer-based therapeutic agent in clinical use (Kourlas and Schiller, 2006).  
Macugen
®
 was approved for clinical use in 2005 and it did not exhibit any intrinsic 
toxicity when evaluated in preclinical studies (2002; 2003; Drolet et al., 2000). The 
only side effect reported arises almost exclusively from the injection procedure rather 
than the drug itself (Gragoudas et al., 2004).    
 
The cytotoxicological data observed in this study further suggests that B40 in 
particular and aptamers in general may be safer than most ARVs. This argues for the 
development of B40 aptamer and related anti-gp120, HIV-1 neutralizing aptamers 
(Khati et al., 2003) as new ARVs (entry inhibitors) with no cytotoxicity. While entry 
inhibitors such as the B40 aptamer are expected to be less or not toxic because they 
act extracellularly, the results of this study should be treated with caution because 
there may be in vitro artifact. A key challenge now is to evaluate the efficacy, 
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pharmacokinetics and toxicity of B40 and related aptamers in a more dynamic in vivo 
animal model in preclinical studies. 
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Chapter Summary 
HIV-associated cardiomyopathy (HIVCM) is of clinical concern in developing 
countries were access to highly active antiretroviral therapy (HAART) is limited. 
Here we further elucidated the aetiology and pathophysiology of the disease.  Novel 
approaches to improve its clinical outcomes based on a previously reported HIV-1 
neutralizing anti-gp120 aptamer called UCLA-1were also evaluated. Furthermore, we 
investigated the direct and indirect effects of HIV-1 infection on cultured human 
cardiomyocytes and the mechanisms leading to cardiomyocytes damage and ways to 
mitigate the damage. We established a cell-based model of HIVCM.  We discovered 
that HIV-1 unproductively (i.e. its life cycle is arrested after reverse transcription) 
infects cardiomyocytes.   Furthermore, we found that cell-free virus initiates apoptosis 
through caspase-9 activation, preferentially via the intrinsic or mitochondrial initiated 
pathway. CXCR4 receptor-using viruses were stronger inducers of apoptosis than 
CCR5 (R5) utilizing variants. HIV-1 induced apoptosis of cardiomyocytes was 
mitigated by the UCLA1 aptamer. However, UCLA1 had no protective effective on 
cardiomyocytes when apoptosis was triggered by HIV-infected monocyte-derived 
macrophages (MDMs). Moreover, when HIV-1 was treated with UCLA1 prior to 
infection of MDMs, it failed to induce apoptosis of cardiomyocytes.  Taken together, 
this data suggest that cell-free virus causes a mitochondrial initiated apoptotic 
cascade, which signal through caspase-9, whereas MDM-associated HIV-1 causes 
apoptosis predominantly via the death-receptor pathway, mediated by caspase-8. 
UCLA1 protects cardiomyocytes from caspase-mediated apoptosis, directly by 
binding to HIV-1 and indirectly by preventing infection of MDMs. 
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1.0 - Introduction 
 
Chronic, long-term HIV-1 infection causes a broad range of clinical complications, 
some of which remain poorly elucidated. One such disease is HIV-associated 
cardiomyopathy (HIVCM). This disease affects the cardiovascular system and is 
brought about by the gradual deterioration of cardiomyocytes (CM) due to chronic 
HIV-1 infection.  This pathology has a broad spectrum of aetiologies ranging from 
secondary infections in immunocompromised patients, mostly in third-world countries 
(Magula and Mayosi, 2003; Ntsekhe and Hakim, 2005; Ntsekhe and Mayosi, 2008), 
to side effects associated with HAART (Barbaro, 2003). There is however an 
increasing body of clinical and experimental data that points to a direct role of HIV-1 
and its associated proteins as important causes of HIVCM (Fiala et al., 2004; Kan et 
al., 2005; Kan, Xie, and Finkel, 2000; Kan, Xie, and Finkel, 2006; Twu et al., 2002). 
HIV-1 infection of human CM has been observed in cardiac biopsies of HIV positive 
patients (Grody, Cheng, and Lewis, 1990; Herskowitz et al., 1994; Lipshultz et al., 
1990), although its outcome is controversial. More clear is the role played by its 
structural, surface envelop glycoprotein called gp120, which has been reported to 
cause apoptosis of murine CM (Fiala et al., 2004; Kan et al., 2005; Kan, Xie, and 
Finkel, 2000; Kan, Xie, and Finkel, 2006; Twu et al., 2002). The cardio toxic effects 
are believed to be triggered in a caspase-dependent, mitochondria-initiated fashion, 
when gp120 interacts with the CXCR4 receptor on the surface of CM (Yuan et al., 
2008). This in turn results in the induction of a negative ionotropic effect through 
increase in nitric oxide (NO) production via p38 mitogen activated protein kinase 
(p38 MAPK)-iPLA2-troponin I initiated NF-κB activation (Kan et al., 2005; Kan, 
Xie, and Finkel, 2000; Kan, Xie, and Finkel, 2006). The end result of NO production 
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is free-radical insult through the formation of reactive oxygen species (ROS), leading 
to the loss of mitochondrial membrane potential and membrane permeabilization, in a 
Bcl-2-inhibitable manner (Green and Reed, 1998; Kroemer, Dallaporta, and Resche-
Rigon, 1998). The exact pathway is not fully understood but leakage of cytochrome c 
into the cell cytosol following permeabilization of the mitochondrial membrane 
triggers the activation of the caspase 9/3 complex eventually culminating in nuclear 
DNA fragmentation (Budihardjo et al., 1999).  
The apoptotic signal is not restricted to host’s cell interaction with viral proteins. 
Cytokines secreted by HIV-infected cells, primarily infiltrating macrophages, also 
play a role in the development of HIVCM. Furthermore, evidence suggests that 
tumour necrosis factor (TNF) might be the main cause in murine cells, by interacting 
with the its respective death receptor, TNF-R1, leading to extrinsic or death-receptor 
mediated apoptosis (Finkel et al., 1992; Monsuez et al., 2007). However, in vitro 
apoptosis triggered by gp120 is initiated preferentially through the CXCR4 receptor 
than the death-receptor. Nonetheless, analysis of cardiac biopsies revealed strong 
expression of both caspase-9 and TNF, which was detected in infiltrating 
inflammatory cells of HIVCM patients, but not in HIV-infected patients without 
HICVM, making a strong argument towards death-receptor initiated apoptosis in vivo 
(Twu et al., 2002). Therefore, there is a growing body of evidence suggesting that 
both pathways are at play, but why and under which conditions each pathway is 
favoured remains to be investigated. In this chapter, we report the HIV-1 infection 
kinetics of human CM as well as the associated apoptotic pathways and receptors 
involved during HIV-CM interaction. We also show that a shortened and synthetic 
derivative of gp120 binding and HIV-1 broadly neutralizing aptamer called UCLA1 
mitigated HIV-initiated apoptosis in CM (Mufhandu et al., 2010 unpublished data). 
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2.0 – Materials and methods 
 
2.1 - Cell cultures 
 
The human cord-blood stem cell-derived cardiomycocytes (CM) were purchased from 
Celprogen (USA) and cultured in Human Cardiomyocyte Expansion Media as 
previously described (Lopes de Campos et al., 2009).  Briefly, the cells were cultured 
at 37°C, 5% CO2 in tissue culture flasks and 96 well plates containing a proprietary 
growth matrix purchased from Celprogene. 
  
Peripheral-blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque™ PLUS 
(GE Healthcare, USA) density gradient centrifugation from heparinised human buffy 
coats of normal, HIV-negative donors and cultured as previously described(Khati et 
al., 2003). Briefly, PBMCs were harvested by centrifugation and seeded on tissue 
culture flasks (Corning) at a density of 2 ×10
6
 cells/ml in RPMI medium containing 
20% fetal bovine serum (Sigma-Aldrich) followed by stimulation with 
phytohemagglutinin (PHA) and treatment with interleukin-2 (IL-2) as described(Khati 
et al., 2003).   Monocyte derived macrophages (MDMs) were isolated from PBMCs 
by adherence and cultured on chamber slides (Lab-Tek, Nunc, USA) in X-VIVO 10 
medium (BioWhittaker) supplemented with 2 % autologous for 7 days. After 7 days 
incubation, differentiated MDMs were typed by flow cytometry using an antibody 
directed against the CD68 cell surface receptor (R&D Systems, USA) and detected 
with a secondary FITC-conjugated (KPL, USA).   
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2.2 - HIV-1 isolates 
 
A panel of 7 previously reported(Cilliers et al., 2005; Coetzer et al., 2006) clinical 
isolates of HIV-1 subtype C were used in this study. They were grouped according to 
co-receptor utilization. A total of two R5 tropic viruses (SW2, SW4), two X4 viruses 
(SW12 and TM46b) and three R5/X4 viruses (CM9, DU179-05-99, RP1 and SW30) 
were respectively used to infect cells. Virus conditioned media (cond media) was 
prepared from day 5 culture supernatants of HIV-infected PHA-stimulated IL-2 
treated PBMCs.  
 
2.3 -  Antiretrovirals  
 
Zidovudine (AZT) and AMD3100 were obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH, USA. 
 
2.4 - UCLA1 anti-gp120 monoclonal aptamer  
 
UCLA1 is a shortened derivative of B40t77 RNA aptamer(Dey et al., 2005) produced 
using solid-phase synthesis as described(Cohen et al., 2008). The UCLA1 aptamer is 
capped and stabilized by addition of an inverted thymidine at the 3′-end and a 
dimethoxyltrityloxy-(CH2)6-SS-(CH2)6-phospho linker at the 5′-end as described 
(Cohen et al., 2008). 
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2.5 - PCR detection of proviral DNA in CM 
 
A total of 50,000 CM or PBMCs cultured in 96-well plates (Corning, USA) were 
exposed to HIV-1 at a concentration of 200 ng/ml p24. Virus-containing supernatant 
we pre-treated with 400 U/ml of DNase I in 5 mM MgCl2 for 1 h at room 
temperature, to remove any pro-viral DNA that may interfere with the PCR detection. 
Cultures we done in the presence or absence of 500 nM of the entry inhibitor 
AMD3100, 100 nM RANTES (regulated upon activation, normal T-cell expressed, 
and presumably secreted) or 100 nM of UCLA1 aptamer. The infection was facilitated 
by spinoculation at 1220 g, 32 ºC for 1 h. The virus-infected cells were further 
incubated at 37 ºC, 5 % CO2 and harvested at 0, 2, 4, 6, 24 h and 6 days respectively. 
Prior to harvesting, the cell monolayer was washed 6 times with 150 μl of warm PBS 
(Lonza, USA). The cells were incubated for 2 h at 55 ºC in 200 μl of lysis buffer 
containing 2 mg/ml of protein kinase, 0.45 % NP-40 (Roche, USA) and Tween-20 
(Sigma-Aldrich, USA), 5 mM MgCl2 and PCR buffer (Promega, USA). Following 
protein digestion and inactivation of proteinase K (10 min at 95 ºC) the cell lysate was 
subjected to PCR amplification as previously described(Schmidtmayerova et al., 
1998).  
 
2.6 - Detection and modulation of HIV-1 initiated apoptosis in cultured CM 
by TUNEL 
 
Cardiomyocytes seeded at a density of 20,000 cells/well were treated either with 
culture medium (mock-treatment), 500 nM of AMD3100,  100nM RANTES, 100 nM 
of Z-IETD-FMK, a preferential caspase 8 inhibitor (casp8i, Promega, USA), 100 nM 
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Z-LEHD-FMK, a preferential caspase 9 inhibitor (casp9i, Promega, USA) or 100 nM 
UCLA-1 for 1 hour at 37
o
C in the CO2 incubator. Cells were then exposed to HIV-1 
subtype C clinical isolates at 30 ng/ml p24. After 3 days of incubation, the cell 
monolayers cultured in flat-bottom 96-well plates (Corning, USA) were fixed in 1% 
(w/v) paraformaldehyde and washed twice with 200 μl of a proprietary wash buffer 
(Guava Technologies, USA). The cells were then resuspended in 25 μl of a Brd-UTP 
labelling mix (Guava Technologies, USA) and incubated for 60 min at 37 ºC. At the 
end of the incubation a volume of 200 μl of a proprietary wash buffer from the same 
manufacturer was added and the cells were harvested by centrifugation. The cells 
were then resuspended in 50 μl of the anti-BrdU-TRITC staining mix for 30 min at 
room temperature. A volume of 150 μl of rinsing buffer was added and the cells were 
analysed in a Guava EasyCyte Plus flow cytometer (Guava Technologies, USA). Data 
was analysed using the TUNEL program in the Cytosoft data acquisition and analysis 
software, Version 5.2.  A total of 2000 events were acquired at a time and each well 
was acquired in triplicate. The results were displayed in a dot plot relating forward 
scatter (FSC) over fluorescence intensity (PM1) as well as a histogram (PM1 
fluorescence intensity vs. number of events). The general apoptosis inducer 
staurosporin (Sigma-Aldrich, USA) was used as a positive control for TUNEL 
staining. 
 
2.7 - Cardiomyocyte apoptosis in HIV-infected MDM co-cultures 
 
Day 7 monocyte derived macrophages (MDMs) seeded at a density of 50,000 
cell/well in a 24 well tissue culture plate (Corning, USA) were infected with R5 and 
dual-tropic viruses (30 ng/ml, p24) for 24 h in a total volume of 200 μl of X-VIVO 10 
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medium (BioWhittaker) supplemented with 2 % autologous serum. The cells were 
then washed 3 times with an equal volume of PBS followed by the addition of 50,000 
uninfected CM. To investigate apoptotic triggers and modulators, cells were cultured 
in the presence or absence of a TNF-α inhibitor (TNF-Ra, R&D Systems, USA), 
AMD3100, casp8i, casp9i and UCLA-1. Controls included mock-infected and 
infected CM and MDM alone and uninfected CM-MDM co-cultures. Following two 
days of exposure the cell monolayer was washed twice with warm PBS prior to 
trypsin (Lonza, USA) treatment. The strong adhesion and resistance properties of 
MDM were exploited to recover the less adherent CM. A 2 min trypsin treatment at 
37 ºC was enough to recover over 95 % of the CM but less than 5 % of the 
macrophages, thereby minimizing cross-contamination. MDM contamination of CM 
cultures was determined by flow cytometry using a 1:200 dilution of a  FITC-
conjugated antibody directed against the CD4 cell surface receptor, which is absent on 
CM. The CM were then stained for TUNEL detection as described above. 
 
2.8 - Indirect immuno-fluorescence for Cytochrome c release detection in 
HIV-exposed CM 
 
Cardiomyocytes were either mock-infected or infected with the HIV-1CM9 dual tropic 
strain for 2 days in the presence of either 100 nM of casp8i; 100 nM of casp9i or 100 
nM of UCLA1. For all casp8i and casp9i, the inhibitors were added to the cell 
monolayer 2 h prior to infection. The UCLA1 aptamer was first incubated with the 
virus for 1 h before infection. Following 2 days of incubation the cells were harvested, 
fixed, stored and washed as above. A total of 20,000 cells/well in 96-well, U-bottom 
plates, were treated with 5 μg/ml of mouse-anti human cytochrome c monoclonal 
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antibody (Santa Cruz Biotechnology, Inc., USA) in a volume of 20 μl for 1 h at 37 ºC. 
The cells were then harvested by centrifugation, washed twice in an equal volume of 
PBS and counter stained with 1 μg/ml of Alexa Fluor 514 goat anti-mouse polyclonal 
antibody (Invitrogen, USA) in a 50 μl volume for 30 min at room temperature. At the 
end of the incubation, rinsing buffer was added up to 200 μl and the cells were 
analysed in the Guava EasyCyte Plus flow cytometer (Guava Technologies, USA). 
 
2.9 – Caspase-8 and -9 enzyme activity and cell viability 
 
CM seeded in 96-well tissue culture plates (Corning, USA) at a density of 10,000 
cells/well in a volume of 150 μl of proprietary growth media (Celprogen, USA). The 
cells were then exposed to eleven different conditions, namely 1 - media alone, 2 - 
conditioned media, 3 - HIV, 4 - 100 μM of preferential caspase 8 inhibitor Z-IETD-
FMK (casp8i) (Promega, USA), 5 - 100 μM of preferential caspase 9 inhibitor Z-
LEHD-FMK (casp9i) (Promega, USA), 6 - conditioned media and 100 μM Z-LEHD-
FMK, 7 - conditioned media and 100 μM  Z-IETD-FMK, 8 - conditioned media and 
100 nM UCLA1 aptamer, 9 - HIV pre-incubated for 1 h with  100 nM of UCLA1 
aptamer, 10 - HIV and 100 μM  Z-LEHD-FMK, 11 - HIV and 100 μM  Z-IETD-FMK 
and harvested daily for 7 days. The harvesting involved the storage of the 96-well 
plates at -80 ºC. On day 7, the plates were allowed to equilibrate to room temperature 
followed by quantification of caspase 8 and 9 activity as well as cellular ATP levels, 
using the Caspase-Glo
®
8, Caspase-Glo
®
9 and the CellTiter-Glo
®
 luminescence-based 
detection kits as instructed by the supplier (Promega, USA). Wells containing media 
alone were used as controls for background luminescence and subtracted from the test 
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values. The results were expressed as relative light units (RLUs) and plotted in a 
graph relating RLU to number of day. 
 
3.0 - Results  
 
3.1 - HIV-1 infection of CM is co-receptor independent and abortive 
 
The ability of HIV to invade cultured cardiomyocytes based on co-receptor tropism 
was accessed as was the virus life cycle once inside the host. 
Cultured human CM were infected by all the R5, X4 and R5/X4 subtype C HIV-1 
isolates tested in the presence or absence of respective co-receptor inhibitors as 
evidenced by the presence of proviral DNA (Table 1). This contrasted with the 
successful inhibition of infection of PBMCs by all subtype C HIV-1 isolates in the 
presence of specific inhibitors of the relevant co-receptors (Table 1). Furthermore, the 
synthesis of proviral DNA and its dose-dependent inhibition by AZT (Figure 1), 
suggested that HIV-1 infects CM, undergoes reverse transcription but does not 
integrate into the host’s genome. It also showed that the pro-viral DNA is synthesised 
inside the host by the viral reverse transcriptase and is not an artefact caused by the 
presence of residual pro-viral DNA in the viral supernatant even after DNase 
treatment. Strengthening this evidenced was the time-dependent decrease in proviral 
DNA as observed by the peak in pro-viral DNA load 2 h post infection and 
subsequent decrease to almost undetectable levels after 24 h and complete absence 
after 6 days (Figure 1). In contrast with the infection kinetics observed in PBMCs, 
there is a time-associated increase of pro-viral DNA, indicative of pro-viral DNA 
amplification and hence productive infection (Figure 1).   
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Table 1:  HIV-1 infection of cultured human CM and primary PBMCs. The presence 
of pro-viral DNA as indicated by the presence of a 539 bp fragment amplified from 
the U3/U5 region was indicative of viral entry and is shown as +. PCR negative 
samples were considered entry negative and are shown as -. 
 
Entry Inhibitors 
Untreated 
AMD3100 
(500 nM) 
RANTES (100 nM) UCLA1 (100 
nM) 
HIV Strain Tropism CM PBMCs CM PBMCs CM PBMCs CM PBMCs 
SW2 R 5  + + + +     + +  + - + - 
SW4 R 5  + + + + + - + - 
          
SW12 X4 + + + - + + + - 
TM46b X4 + + + - + + + - 
          
cm9 R5X4 + + + - + + + - 
DU179 (05-99) R5X4 + + + + + + + - 
RP1 R5X4 + + + + + + + - 
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Figure 1: Kinetics of HIV infection of CM and PBMC. (A) Agarose-gel 
electrophoresis of the PCR-amplified U3/U5 region of CM9-infected culture lysates. 
The 539 bp fragment indicates the presence of proviral DNA. Cell lysates were 
analysed at 0, 2, 4, 6, 24 h and 6 days post infection. A 288 bp region of the gene 
coding for α-tubulin was amplified and resolved at the same time to ensure equal 
loading of the wells. (B) CM were exposed to serial dilutions of AZT at a maximum 
concentration of 1 μM for 2 h prior to infection. Two hours post-infection, cell lysates 
were analysed for the presence of proviral DNA as above. Agarose-gel 
electrophoresis of cell-free virus culture lysates were digested with DNaseI for 1 h 
prior to infection. 
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3.2 - Apoptosis of CM is HIV-1 tropism-dependent and is triggered 
predominantly by the interaction of HIV-1 with the CXCR4  
 
The consequences of the interaction between HIV-1 of different co-receptor tropisms 
and the chemokine receptor CXCR4 on CM was investigated.  Induction of apoptosis 
in CM by X4 viruses was on average 3 times higher than that of R5 viruses (54 % ± 
6.6 % TUNEL positive for X4 viruses vs. 18 % ± 5.3 % for R5 viruses, Figure 2). 
Dual-tropic (R5/X4) viruses also induced considerably more apoptosis in CM than 
R5-tropic viruses by a magnitude of 2.7 (Figure 2). Almost complete inhibition of 
apoptosis induced by R5 viruses was observed in the presence of the highly selective 
CXCR4 antagonist, AMD3100 as well as the UCLA1 aptamer resulting in an average 
cellular protection against apoptosis from 82 ± 5.0 % to 97 ± 2.0 % (P = 0.024) 
(Figure 2). Apoptosis was even more pronounced in CM infected with X4 and dual 
tropic viruses where, on average, the TUNEL positive population decreased 7.4 fold, 
from 52 ± 6 % to 5 ± 3 % (P < 0.001) in the presence of AMD3100 only (Figure 2). 
The UCLA1 aptamer did not show as strong a protective effect as AMD3100 but cell 
survival still decreased nearly 4 fold, from 52 ± 6 % to 13 ± 6 % (P < 0.001) when 
compared to untreated controls (Figure 2).  On the other hand, RANTES, the 
physiological ligand for the CCR5 chemokine receptor, had no statistically significant 
effect in protecting CM from HIV-1 associated apoptosis when compared to untreated 
controls (P = 0.62) (Figure 2). Therefore apoptosis is triggered through the CXCR4 
receptor and is stronger when initiated by X4 utilizing viruses. The synthetic CXCR4 
receptor antagonist protects CM from apoptosis as does UCLA1, albeit to a lesser 
extent. 
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Figure 2: Quantification of the relationship between chemokine co-receptor 
utilization and apoptosis initiation by TUNEL staining of CM, 3 days post infection 
with HIV-1. CM were exposed for 3 days to: mock infection; HIV; HIV and 
AMD3100; HIV and RANTES; HIV and casp8i; HIV and casp9i; HIV andUCLA1. 
After 3 days he cells were stained for TUNEL detection with a TRITC conjugated 
antibody directed against Brd-UTP Fluorescent labelled cells were analysed in the 
Guava EasyCyte Plus flow cytometer (Guava Technologies, USA) using the Cytosoft 
software, Version 5.2. A total of 2000 events were acquired for both assays and the 
data is representative of 3 independent experiments. The data was acquired in dot 
plots relating fluorescent intensity to forward scatter and presented as bar graphs as 
percentage of the total cell population that was TUNEL positive. Statistically 
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significant TUNEL positive results, as indicated by the t-test, are marked as: *, P < 
0.05; •, P < 0.005; º, P < 0.0005.  
 
3.3 - The extrinsic or death-receptor pathway is the preferred apoptotic 
mechanism in CM co-cultured with HIV-infected MDM 
 
There is evidence suggesting that HIV-1 infected, infiltrating macrophages in cardiac 
tissue are strongly associated with caspase-dependent CM apoptosis.  
There was no statistically significant difference in apoptosis modulation between 
untreated CM exposed to HIV-1 infected MDMs with all the 5 strains in the presence 
of AMD3100 (P > 0.09), except for DU179-99, where  there was a decrease in 
TUNEL positive cells from 24.33 ± 3.05 % to 15.66 ± 3.21 % (P = 0.027) (Figure 3). 
No significant apoptosis modulation was achieved in the presence of the UCLA1 
aptamer (P > 0.07) (Figure 3). Strong protection against apoptosis was achieved in 
the presence of TNF-R1 (4.6 fold ± 2.6, P < 0.02) and casp8i (5.3 fold ± 2.2, P < 
0.02), two key components of the extrinsic apoptotic pathway (Figure 3). The X4-
tropic viruses induced apoptosis 1.35 times more efficiently than the dual tropic 
viruses, although this difference was not statistically significant (P = 0.36) (Figure 3). 
Thus, HIV-1 infected macrophages induce apoptosis in uninfected CM via the death 
receptor pathway and can only be mitigated by soluble TNF-R1. Neither UCLA1 nor 
AMD3100 had any protective effect. 
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Figure 3: CM apoptosis in a co-culture model with HIV-infected MDM. MDM were 
infected with the R5-tropic viruses SW2, SW4 or the dual tropic viruses CM9, DU179 
(99) and RP1 for 24 h. Uninfected CM were added and the co-cultures were then 
incubated for a further 24 h. Following incubation, the cell monolayers were stained 
for TUNEL detection. Statistically significant decreases in TUNEL positive cells, as 
indicated by the t-test, are marked as: *, P < 0.05 and •, P < 0.005 º, P < 0.0005 
respectively. 
 
3.4 - The intrinsic or mitochondrion-initiated apoptosis is the preferred 
death-signal pathway mediated by caspase 9 activation 
 
Cytochrome c leakage from the mitochondria as well as caspase-9 activation are 
markers of the intrinsic mitochondrial-initiated pathway and caspase-8 activation is 
the canonical caspase of the extrinsic apoptotic pathway. 
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Untreated control cells showed a viable, healthy population with only 2.4 ± 0.7 % 
staining positive for Cytochrome c release (Figure 4 A). This contrasted with the 
strong staining in HIV-infected cells, accounting for 41.77 ± 3.0 % of the total 
(Figure 4 B). The preferential caspase-8 inhibitor conferred a minor but significant 
protection against apoptosis (32.2 ± 5.3 % apoptotic cells) (Figure 4 C). Conversely, 
very strong apoptosis inhibition was achieved in the presence of the preferential 
caspase-9 inhibitor, which effectively reduced the number of apoptotic cells to 14.3 ± 
3.6 % of the total cell population (Figure 4 D). UCLA1 also had a significant 
protective effect whereby 22.4 ± 4.4 % of cells stained positive (Figure 4 E).  
 
There was an inversely proportional link between total cellular ATP, which was a 
measure of cellular viability, and caspase-9 activation during HIV-1 infection (Figure 
5 A). A drop in ATP levels was observed 1 day after peak caspase-9 activity and 
subsequent recovery at day 5 correlated with a decrease in caspase-9 levels. Both 
caspase-9i and UCLA1 had a protective effect in cell viability as indicated by an 
exponential increase in cellular ATP from day 3 to 7.  
 
Caspase 8 activation in HIV infection did not rise significantly from the untreated 
control cells or any other test condition (Figure 5 B). Furthermore there was no 
statistical difference between cells treated with casp8i or UCLA1 and untreated, 
infected cells up to day 3 (P = 0.5). There was however an exponential increase in 
enzyme activity levels in infected, UCLA1 treated cells, very similar to untreated 
controls from day 3 to 7. The opposite was observed with casp8i treated cells, where 
there was a decline in enzyme activity up to day 4 followed by an increase up to day 
7.  
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Peak caspase-9 enzyme activity was observed two days post-exposure to HIV-1, 
resulting in a 9.3 fold increase in enzyme levels, when compared to the untreated 
controls (P = 0.01) (Figure 5 C). This was followed by a sharp decrease in enzyme 
activity relative to control cells. The preferential caspase-9 inhibitor only allowed for 
a 2.62 fold increase in enzyme activity in the presence of HIV-1 after two days of 
treatment (P = 0.02). UCLA1 also had a modulatory effect in caspase-9 activity 
during infection (RLU = 2410, P = 0.001), albeit weaker than that of casp9i (RLU = 
1515, P = 0.02). All other test conditions did not significantly affect caspase 9 levels 
(P > 0.07) during the entire course of the experiment. Therefore both intrinsic and 
extrinsic apoptosis are triggered by cell-free HIV in CM, however the extrinsic 
pathway is dominant as the high levels of caspase-9 activity indicated. Caspase 9 is 
also a key player in CM apoptosis since its inhibition resulted in almost complete 
abrogation of apoptosis and inhibition of caspase-8 had a much less pronounced 
effect. UCLA1 obstruction of the CXCR4 binding site of gp120 also blocked 
apoptosis. Therefore apoptosis is initiated by interaction of cell-free virus with the 
CXCR4 chemokine receptor the signal is transduced via the preferential activation of 
caspase-9. 
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Figure 4: Cytochrome c release in HIV-infected CM. CM were either: (A) mock 
infected; (B) HIV-1 infected; (C) infected in the presence of casp8i; (D) infected in 
the presence of casp9i and (E) infected with virus pre-incubated with UCLA1. Data 
were presented in dot plots relating fluorescent intensity as a measure of Cytochrome 
c release against forward scatter. 
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Figure 5: caspase-8 and -9 activity in CM infected with HIV-1. CM were exposed to: 
media alone; conditioned media; HIV; 50 μM of casp8i; 50 μM of casp9i; conditioned 
media and 50 μM of casp8i; conditioned media and 50 μM of casp9i; conditioned 
media and 100 nM UCLA1 aptamer; HIV and 50 μM of casp8i; HIV and 50 μM of 
casp9i; HIV pre-incubated for 1 h with 100 nM of UCLA1 aptamer. Cells were 
harvested daily for 7 days. (A) ATP levels were measured as a correlate of cell 
viability; (B) caspase-8 and (C) caspase-9 activity as indicators of extrinsic and 
intrinsic apoptosis respectively. All assays were luminescence-based and presented as 
graphs relating RLU to number of days.  
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4.0 – Discussion 
Apoptosis has been observed during HIV infection but its aetiology remains poorly 
understood. In the current study we elucidated some key mechanisms of CM 
apoptosis during HIV-1 infection by employing a range of specific apoptosis 
inhibitors as well as the HIV-1 neutralizing aptamer UCLA1. Firstly, we accessed the 
ability of HIV-1 to infect CM. We used two R5, two X4 and three R5X4 subtype C 
HIV-1 and observed a tropism-independent infection (Table 1). The formation of pro-
viral DNA (Figure 1A), further suggests that HIV-1 can enter and infect human 
cardiomyocytes; albeit unproductively.  Entry of HIV-1 into cardiomyocytes is 
thought to be mediated by binding of the virus to ganglioside GM1, inducing a re-
modelling of the cell membrane and formation of microvilli thereby entangling the 
virions and subsequent internalization via macropinocytosis (Fiala et al., 2004; Liu et 
al., 2002; Twu et al., 2002). The lack of entry inhibition in the presence of known 
coreceptor antagonists (Table 1) further strengthens the argument for a receptor-
independent mode of entry. Nonetheless the virus was unable to complete its life 
cycle, as indicated by the time-dependent decrease in pro-viral DNA upon infection 
(Figure 1A) as well as by the absence of p24 antigen in culture supernatants (Figure 
1.C). It is likely that the pro-viral pre-integration, nuclear-localization complex is 
never formed resulting in a time-dependent degradation of the pro-viral DNA in the 
cytoplasm. There is also in vivo, clinical evidence for direct infection of CM in AIDS 
patients (Grody, Cheng, and Lewis, 1990; Herskowitz et al., 1994) but these studies 
were limited to detecting viral nucleic acid and proteins in cardiomyocyte biopsies. 
No studies were undertaken to probe into the viral replication cycle in the infected 
tissue. 
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Experimental data has also revealed that although the virus cannot complete its life 
cycle, it was still capable of inducing significant caspase-dependent apoptosis. 
Furthermore, entry was not required for apoptosis since the apoptotic signal was 
initiated by interaction with the cell-surface receptors, the CXCR4 chemokine 
receptor and the TNF-R1 death receptor. The predominant apoptotic pathway varied 
from CXCR4-triggered, mitochondrion-initiated to CD95/Fas-ligand initiated, 
depending on the culture conditions as previously reported in T cells (Bottarel et al., 
1999; Roggero et al., 2001). In the absence of MDM, HIV-1 directly interacts with the 
CXCR4 chemokine receptor on CM, resulting in cell death. This death-inducing 
signalling however is significantly stronger in X4 and dual tropic viruses, possibly 
because these viruses interact with higher affinity with the CXCR4 receptor than R5 
tropic viruses. The UCLA1 aptamer binding site maps to the CCR5/CXCR4 binding 
region of gp120 on HIV-1 (Cohen et al., 2008; Dey et al., 2005; Khati et al., 2003), 
which satisfactory explains its strong anti-apoptotic properties, very similar to that 
brought about by the highly selective CXCR4 receptor ligand AMD3100. This 
observation, together with Cytochrome c leakage into the cell cytosol points to a 
CXCR4/HIV interaction as the key apoptosis trigger as recently reported in murine 
CM (Yuan et al., 2008) and earlier in primary human macrophages (Herbein et al., 
1998), resulting in mitochondrial initiated apoptosis (Roggero et al., 2001; Twu et al., 
2002) independent of death-receptor mediated signalling (Adachi, Gottlieb, and 
Babior, 1998). It has been reported that the CXCR4 receptor is involved in both 
caspase-dependent and caspase-independent apoptosis induction. There is however 
some controversy regarding the circumstances under which each pathway is favoured. 
Some groups have reported that caspase-dependent apoptosis requires interaction with 
both CD4 and CXCR4 receptors, and in the absence of CD4, the apoptotic signal 
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initiated by CXCR4 is caspase-independent (Bottarel et al., 1999; Nardelli et al., 
1995; Vlahakis et al., 2001). On the other hand, an elegant and more recent study 
conducted by Roggero and co-workers revealed that CXCR4 cooperation with a CD4 
signal was not required for the induction of mitochondrial-mediated apoptosis 
(Roggero et al., 2001). Furthermore, deletion of the cytoplasmic tail of CD4 in cells 
co-transfected with both CD4 and CXCR4 did not shift the apopotic pathway from 
caspase-dependent to caspase-independent (Biard-Piechaczyk et al., 2000; Jacotot et 
al., 1997). A strong argument in this favour can also be made in our study, in that we 
detected caspase activity in the absence of CD4 transcription and expression (results 
not shown).  
 
Furthermore, we observed that both apoptotic pathways were intimately related with 
caspase activity, an observation not supported in a previous study using T-cells 
(Vlahakis et al., 2001). This study argues that X4 tropic HIV-1 env glycoprotein 
initiates a caspase-independent apoptosis signal. The 9.3 fold increase in cellular 
caspase 9 levels, and the improved cell survival brought about by its inhibition, 
further strengthens the argument for a caspase-dependent apoptotic pathway. 
Comparing these two studies may not be possible at all not only because different cell 
types were investigated but also due to the fact that we made use of fully infectious, 
cell-free virions and not pure preparations of recombinant, monomeric gp120, which 
in its native form, is trimeric and could elicit different apoptotic responses. Beyond 
this we found evidence for a second, caspase-dependent apoptotic pathway, initiated 
at the TNF-R1 death receptor in the presence of HIV. Although the peak in caspase 8 
activity was not statistically significant, there was a significant degree of cellular 
protection when HIV-exposed CM were treated with the preferential caspase 8 
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inhibitor Z-IETD-FMK. Caspase 8 is regarded as being a key initiator of death 
receptor mediated apoptosis and under physiological conditions, it is primed by the 
TNF superfamily member of related apoptosis triggers (Boldin et al., 1996; Muzio et 
al., 1996). Our case for extrinsic apoptosis rests on the merit of its inhibition rather 
than on upregulation of its downstream effector caspase.  
 
The MDM-cardiomyocyte co-culture model shows a drastic shift in the preferential 
apoptotic trigger, towards the extrinsic pathway, initiated by interaction with TNF-R1 
by secreted death-signalling molecules produced by infected MDMs. Under these 
conditions apoptosis progressed with much more rapid kinetics, measured in hours as 
opposed to days when initiated by the CXCR4 receptor. The almost complete 
abrogation of apoptosis in the presence of TNF-R1 as well as casp8i sheds further 
light into preferential apoptotic pathways and receptor trigger during HIV-1 
infection/exposure of CM. In this scenario, the UCLA1 aptamer had no impact in 
apoptosis modulation, which was expected since the extrinsic or death-receptor 
initiated apoptosis is triggered by host, rather than viral factors. Nonetheless, by 
preventing macrophage infection, UCLA1 can strongly modulate both apoptotic 
pathways. A further advantage of UCLA1 over conventional antiretrovirals is that it 
directly neutralizes the deleterious effects of cell-free virus by preventing it from 
interacting with the CXCR4 chemokine receptor. In fact, protease-inhibitors used in 
HAART give rise to non-infectious virions with fully functional envelope 
glycoproteins that have been observed to lead to apoptosis of non-infected CD4
+
 and 
CD8
+
 T-cells (Esser et al., 2001). Since the ratio of circulating non-infectious to 
infectious virions is exponentially greater (Dimitrov et al., 1993; Piatak et al., 1993), 
the role played by these non-infectious virus particles in the progression to 
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cardiovascular disease cannot be ignored, particularly in cell expressing the CXCR4 
chemokine receptor. Therefore, it is perhaps erroneous to assume that because these 
viral particles are not capable of productive infection, that they play no role in HIV 
pathogenesis. This argues for the development of a novel class of ARVs, such as 
UCLA1, that can target both cell-free and cell associated virus as a strategy to 
preventive the deleterious consequences of non-productive infection of CM and 
broaden the effectiveness of HAART. 
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Chapter Summary 
The aetiology of HIV-associated cardiomyopathy (HIVCM) is poorly understood due 
to its multifactorial nature as well as the difficulties in generating good cellular and 
animal models. Here, we created a simple cellular model of HIVCM using cultured 
human cardiomyocytes (CM) and primary human macrophages. We successfully 
mitigated CM apoptosis with a non-toxic, previously described RNA aptamer called 
UCLA1, which binds gp120 and broadly neutralizes HIV-1 infectivity. When 
infectious virions were pre-treated with UCLA1, the expression levels of 27 different 
cytokines remained unaltered when compared to infected controls. During co-culture 
with HIV-infected monocytes derived macrophages (MDM), extensive apoptosis was 
observed in CM. However, when cultures were pre-treated with a soluble death 
receptor of the tumor necrosis factor superfamily (TNF-R1) and with neutralizing 
antibodies against the cytokines interleukin-1β (IL-1β) and interleukin-6 (IL-6), singly 
or in combination, there was a significant improvement in CM survival. Recombinant 
IL-6 and IL-1β had no apoptotic effect directly but when combined with TNF, CM 
death was significantly greater than TNF treatment alone. Together, these data show 
that IL-1β, IL-6 and TNF homeostasis are crucial to preserve CM integrity. This was 
achieved in the presence of UCLA-1, which further highlights the utility of the 
aptamer as a potentially safe and effective therapeutic agent to complement current 
ARVs.   
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1.0 - Introduction 
 
Human immunodeficiency virus-associated cardiomyopathy (HIVCM) is a growing 
health concern and is fast emerging as a disease with significant morbidity in long-
term infected HIV-positive patients (Barbaro, 2005b; Lewis, 2000; Magula and 
Mayosi, 2003; Ntsekhe and Hakim, 2005; Ntsekhe and Mayosi, 2008). To date, the 
aetiology and outcome of this AIDS-related pathology remains poorly understood 
(Barbaro, 2003a). The difficulties in dissecting the events that precede the onset of 
HIVCM are increased by the multifactorial nature of the disease. It has been shown 
that virions as well as viral proteins secreted by HIV-infected cells can result in 
significant cardiac damage (Fiala et al., 2004; Jacotot et al., 1997; Lewis, 2001; 
Lipshultz et al., 1990; Twu et al., 2002). Furthermore, cardiotrophic viruses that arise 
due to immunodeficiency (Hajjar et al., 2005; Herskowitz et al., 1994) as well as 
antiretrovirals (Carr and Ory, 2006) have been identified as being important triggers 
of HIVCM. In addition the role of host factors such as pro-apoptotic cytokines 
secreted by infected macrophages in HIVCM pathogenesis is being recognised as a 
pivotal player leading to cardiovascular disease during long-term HIV infection 
(d'Amati, di Gioia, and Gallo, 2001; Lewis, 1989; Liu et al., 2001; Twu et al., 2002). 
Infiltrating, HIV-infected macrophages secrete a broad spectrum of pro-inflammatory 
and immuno-regulatory cytokines. Some of these cytokines have been reported to 
cause extensive apoptosis in non-infected cells located in close proximity to and by 
direct contact with infected cells (Heinkelein, Sopper, and Jassoy, 1995; Herbeuval 
and Shearer, 2006; Nardelli et al., 1995). Pro-inflammatory cytokines such as TNF, 
interleukin-1β (IL-1β) and IL-6 are secreted by macrophages during HIV infection 
and a direct link between high serum levels of these cytokines and cardiomyocyte 
Chapter Four: Cytokine Profiling of CM and MDM During HIV infection 
 
 
 
  95 
 
apoptosis has recently been suggested (Monsuez et al., 2007). Furthermore, high 
levels of IL-1β/6 are strongly correlated with rheumatoid arthritis (de Benedetti et al., 
1991; Hermann et al., 1989; Houssiau et al., 1988; Mayet et al., 1990) and congestive 
heart failure (Long, 2001; Wollert and Drexler, 2001). High concentrations have also 
been detected in cardiac myxomas and cervical and bladder carcinomas (Scheller, 
Ohnesorge, and Rose-John, 2006). Recently, in a 3 year follow up study of patients 
with acute myocardial infarction, IL-6 levels were identified as a key predictor of 
mortality (Tan et al., 2009). In ex-vivo and murine models, IL-1β/6 have been 
associated with decreased cardiac contraction, extensive cardiac remodelling and 
increased mortality (Finkel et al., 1992; Givertz and Colucci, 1998; Li et al., 2005). 
Cardiac pathology caused by these cytokines is further compounded by their ability to 
enhance HIV replication in chronically infected CD4
+
 T cells as well as in MDMs  
(Kedzierska et al., 2003), since there is a strong link between productive viral 
replication and cardiovascular morbidity. Therefore modulation of cytokine 
expression during HIV infection to normal or physiological levels could result in 
significant protection of cardiovascular tissue. The role of IL-1β, IL-6 and TNF 
produced by HIV-infected MDM in CM apoptosis was investigated in our ex-vivo 
model of HIVCM. 
 
Cardiomyocyte (CM) apoptosis during HIV infection is a multifactorial process, 
involving a broad spectrum of differentially expressed cytokines. Moreover, it 
remains to be elucidated whether the apoptotic stimuli from cytokines act in a 
paracrine or autocrine fashion in CM. Finally, if the apoptotic trigger consists of 
cytokines secreted by HIV-infected infiltrating tissue macrophages, it would be of 
significant clinical importance to unravel whether regulating the host’s response 
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would have any benefit in CM survival. This can be a potential therapeutic target, 
particularly if the death signal is restricted to one or two cytokines that can be 
modulated without causing further morbidity to the host. In this study we bridged that 
gap by looking at the differential expression of 27 different cytokines during HIV 
infection in CM, MDMs and co-cultures of HIV-infected MDMs with uninfected CM. 
We observed a significant deviation from homeostatic levels in co-cultures of HIV-
infected MDMs and uninfected CM when compared to mock infected controls, which 
directly correlated with CM death. We then investigated the effects of using a a 
shortened synthetic derivative of anti-gp120 2′-fluoro substituted RNA aptamer with 
broad HIV-1 neutralizing activity called (Cohen et al., 2008; Dey et al., 2005; Khati et 
al., 2003) and minimal cytotoxicity (Lopes de Campos et al., 2009) on CM apoptosis 
and cytokine expression. The advantage of using this aptamer called UCLA1 over 
conventional ARVs in current clinical use is that it interferes with viral entry by 
binding to the CCR5/CXCR4 chemokine co-receptor binding pocket on the viral 
gp120 (Cohen et al., 2008), thereby inhibiting entry, as opposed to interfering with 
post-entry events like most ARVs such as protease and reverse transcriptase 
inhibitors. UCLA1 is also capable of blocking the interaction between the host cells 
and non-infectious virions, which surpass the number of infectious virions by several 
orders of magnitude (Dimitrov et al., 1993; Piatak et al., 1993). Although non-
infectious, these virions still retain their ability to trigger apoptosis in HeLa cells, by 
interacting with the CXCR4 co-receptor (Esser et al., 2001), which has been identified 
as one of the key triggers in CM apoptosis (Yuan et al., 2008).  
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2.0 - Materials and Methods 
 
2.1 - Cells, virus and antibody 
 
Human cord-blood stem cell-derived cardiomyocytes were purchased from Celprogen 
(USA). Cardiomyocytes were cultured in Human Cardiomyocyte Expansion Media 
(Celprogen) and cultured as recommended.  
 
PBMCs were and MDM were isolated from heparinized human buffy coats of normal, 
HIV-negative donors as previously described (Khati et al., 2003). Buffy coats were 
obtained from the South African National Blood Services. PBMCs were cultured in 
RPMI medium containing 20% foetal calf serum (Lonza, USA) and MDM in X-Vivo 
10 supplemented with 2 % autologous serum. 
Following 7 days of incubation, the resulting macrophages were typed via flow 
cytometry using an anti-CD68 antibody (R&D Systems, USA) and detected with a 
secondary FITC-conjugated antibody (KPL, USA). Only cultures containing over 95 
% of CD68
+
 cells were used. 
 
The previously reported CM9 HIV-1 subtype C, CCR5/CXCR4 dual-tropic virus 
strain was used (Cilliers et al., 2005). In order to ensure that the virus containing 
supernatant was free of any viral proteins, the virions were separated from the rest of 
the culture medium by size-exclusion centrifugation, using a 200,000 Kda NMW 
(Millipore, USA) and resuspended in an equal volume of PBS. 
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The HIV-1 broadly-neutralizing monoclonal antibody, IgG b12, was obtained through 
the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH. 
 
2.2 - Culture conditions 
 
Two types of cultures were used: a monoculture, whereby CM and MDM were seeded 
at a density of 50,000 cells/well in separate wells; and a co-culture system where 
50,000 MDM and CM were seeded in the same well in the presence of CM growth 
media. For cell viability studies in co-cultures where it was required to assess both 
cells independently, CM were separated from MDM by trypsin treatment for 5 min at 
37 ºC. Under these conditions, less than 5 % of the harvested cells were MDM as 
assessed by flow cytometry. These cells were then labelled as cond CM and cond 
MDM respectively (denoting conditioned cells). All cultures were either mock 
infected or infected with the HIV-1 clinical isolate, CM9. 
 
2.3 - Virus infectivity assays 
 
A virus titer of 100 ng/ml p24 was incubated for 1 h with 8, ½ log dilutions of 
UCLA1 starting at a maximum concentration of 100 nM of UCLA1. Cells were then 
infected in a total volume of 300 μl with treated virus, untreated virus or left 
uninfected. Supernatants were collected every day after day 3 for 7 days for p24 
ELISA using the Vironostika
®
 HIV-1 p24 antigen detection kit (Biomerieux, France). 
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2.4 - Identification and quantification of cytokine expression by multiplex  
flow cytometry 
 
A total of 200 μl of culture supernatants where harvested 24 h post-infection and 
stored at - 80 ºC. The supernatants where then centrifuged at 14,000 rpm for 10 min at 
4 ºC to remove any solid debris. A total of 50 μl from each sample was analysed for 
expression of a range of 27 different cytokines, via multiplexing using immuno-
magnetic beads-coupled antibodies directed at the cytokines in a Bio-Plex
®
 
Suspension Array System (Bio-Rad, USA). The cytokines assayed were: IL-1β, IL-
1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, 
eotaxin, basic FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF), MIP-1alpha, 
MIP-1beta, PDGF-BB, RANTES, TNF, VEGF. Data was analysed using the Bio-Plex 
Manager Software Version 5.0 as well as GraphPad Prism
®
 Version 3.02. 
2.5 - Cell viability assay 
 
Following 24 h of incubation, cell viability was determined using the ATP-based 
assay CellTiter-Glo
®
 Luminescent Cell Viability Assay (Promega, USA) and used 
according to the manufacturer’s recommendations. Both the plates and the reagent 
were allowed to equilibrate at room temperature. Then an equal volume of reagent 
was added to the wells and further incubated at room temperature for 20 minutes to 
allow for the luminescent signal to stabilize. Following the incubation, the 
luminescent signal was measured in a Modulus
®
 Microplate Reader luminometer 
(Promega, USA) using a count integration time of 1 second. The raw data was 
measured in relative light units (RLUs) and the final results were normalized (i.e. the 
total number of viable cells in the treated samples were respectively subtracted by the 
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total number of viable cells in the cell control, which was not treated with any drug or 
test molecule) and expressed as percentage cell death. Viability of untreated control 
cells was over 97%. Wells containing media alone were used as controls for 
background luminescence and subtracted from the test values. The general formula to 
calculate percentage toxicity was: % of viable cells = [(RLU of drug treated cells - 
RLU of medium control) ÷ (RLU of untreated cell controls - RLU of medium 
control)] × 100. 
 
2.6 - Neutralization of IL-1β, IL-6 and TNF activity in HIV-infected  
MDM, uninfected CM co-cultures 
 
Cytokine neutralizing antibodies were added alone or in combination, at the same 
time as the uninfected CM cultures were seeded with the HIV-infected MDM 
cultures. Antibodies against human IL-1β and IL-6 and the soluble death receptor for 
TNF, TNF-R1 (R&D Systems, USA) were added at a single concentration of 100 nM. 
Following 24 h of co-culturing, CM were harvested as described and ATP levels were 
measured as above as co-relates of cell viability. As controls, CM were co-cultured 
with uninfected MDM in the presence of 100 nM of antibody. The RLUs for control 
cells were used as a set as a point that represented 100 % cell viability from which the 
experimental percentage of cell viability was determined. The data was plotted in a 
bar graph showing antibody treatment against % cell survival. The results represent 
the mean and standard deviation of two independent experiments. 
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2.7 - Treatment of CM with recombinant cytokines 
 
Log-phase CM were exposed to recombinant IL-1β, IL-6 and TNF (R&D Systems, 
USA), singly or in combination, at a starting concentration of 10 ng/ml of each 
cytokine, followed by seven ½ log serial dilutions, in a total final volume of 100 µl. 
Following 24 h exposure, ATP levels were measured as described. The RLUs for 
control cells represented 100 % cell viability from which the experimental percentage 
of cell viability was determined. The minimum concentration of cytokine required to 
kill 50 % of the cells (IC50) was extrapolated from a plot relating percentage cell 
viability against cytokine concentration (ng/ml). The results represent the mean and 
standard deviation of two independent experiments. 
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3.0 - Results 
 
3.1 - UCLA1 inhibits viral replication in PBMCs 
 
Pre-treatment of the HIV-1CM9 clinical isolate with 100 nM of UCLA1 inhibited 
infection of PBMCs by 92.2 ± 3.8 %, as indicated by the near absence of p24, a 
surrogate marker for viral replication, p24  (Figure 1). The neutralization efficiency of 
UCLA1 as indicated by the IC50 value of 8.9 nM, was very close to that of the broad 
neutralizing monoclonal antibody, IgG b12 (IC50 = 2.9 nM), which was used as the 
positive control for HIV neutralization. IgG b12 decreased overall viral replication by 
97.8 ± 0.3 % at 100 nM. 
 
 
 
 
 
 
 
 
Figure 1. Neutralization of HIV-1CM9 infectivity by UCLA1. Virus was incubated 
with UCLA1, at serially diluted concentrations, for 1 h followed by infection of 
PBMCs. After 4 days of incubation, supernatants were analyzed for p24 production as 
a correlate of replication or neutralization. The broad neutralizing monoclonal 
antibody, IgG b12, was used as a positive control for neutralization. Strong 
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neutralization was observed in the presence of UCLA1, with an IC50 of 8.2 nM, close 
to that of IgG b12 (IC50 = 2.9 nM). 
 
3.2 - TNF, IL-1β and IL-6 are strongly up-regulated during HIV infection  
and are restored to pre-infection levels by the UCLA1 aptamer   
 
Basal levels of expression of all measured cytokines in uninfected or mock infected 
CMs were below 150 pg/ml (Figure 2 A). This contrasted with that of MDM where 
the basal levels of most cytokines was above 1000 pg/ml, particularly pro-
inflammatory, was observed (Figure 2 B). Expression of all the 27 cytokines tested 
were significantly higher in MDMs than in CM, except for IL-2, IL-13, Eotaxin, IL-5 
and GM-CSF, where levels were less than 2-fold greater than what was observed in 
CM supernatants (Figures  2 A and B). VEGF was the only cytokine where basal 
levels in CM cultures were greater than in MDM cultures by almost 6-fold (Figures 2 
A and B). MDM+CM co-cultures had a cytokine profile almost identical to that of the 
MDM single cultures except that the levels of all 27 cytokines were lower and not 
cumulative as expected, since there were twice as many cells (Figure 2 C). HIV 
infection had a more pronounced effect on cytokine expression in CM than in MDMs 
or MDM+CM co-cultures. No cytokines were down regulated when compared to 
mock-infected supernatants. In infected MDM and MDM+CM co-cultures, the 
following cytokines increased less than two-fold when compared to uninfected 
controls: IL-4, IL-10, IL-12, IL-15, Eotaxin (Figure  2.B.4), IL-8, IP-10, MIP-1β, 
MCP-1 and RANTES (Figure 2.B.5). Down-regulation was observed only in MDM 
and the co-cultures. A 3.2-fold decrease in the pro-inflammatory cytokine MIP-1α 
concentration (Figure 2.B.5) was observed in MDM-infected cultures (from 20,655 ± 
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269 pg/ml to 6496 ± 173 pg/ml). The homeostatic cytokine PDGF also dropped from 
5573 ± 64 pg/ml to 1688 ± 372 pg/ml, representing a 3.3-fold reduction (Figure 
2.B.6). Both cytokines where also down regulated in infected co-cultures, where a 
3.8-fold decrease for MIP-1α was observed (20,592 ± 161 pg/ml to 4810 ± 51 pg/ml)  
and a 4.3-fold decrease for PDGF (from 834 ± 53 pg/ml to 217 ± 10 pg/ml). 
Furthermore, basic-FGF also dropped from 65 ± 10 pg/ml to 4 ± 1 pg/ml representing 
a 16.3-fold decrease. There were only two cytokines that were up-regulated only in 
MDM and co-cultures but not in CM, namely IFN-γ and TNF. Both remained at 
baseline levels post-infection in CM but in infected MDM a 24-fold increase for IFN-
γ (from 66±1 to 1558±22 pg/ml) and 20-fold for TNF (from 495±8 to 9824±66 pg/ml) 
respectively. The increase in co-cultures was less pronounced with TNF (14-fold 
increase, from 712±30 to 8214±8 pg/ml) but higher for IFN-γ (36-fold increase from 
36±8 to 1249±39 pg/ml). Pre-treatment of the CM9 virus with 100 nM of UCLA1 for 
1 h prior to infection resulted in restoration of cytokine levels to pre-infection levels 
in all cultures (Figure 2). Two key cytokines, IL-1β and IL-6 were strongly up-
regulated upon HIV infection in all 3 culture models (Figures 2.A.5, 2.B.5, 2.C.5). 
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Figure 2: Cytokine profiling during HIV-1CM9 infection. Cytokine expression during 
HIV-infection was assessed in three different cultures:  (A) CM, (B) MDM, (C) 
CM+MDM. Cultures were infected with HIV-1CM9 for 24 h prior to assay. In the 
CM+MDM co-cultures, MDM were infected for 24 h, the infected monolayer was 
washed and fresh growth media was added, together with uninfected CM. Following a 
further 24 h of incubation, the supernatants were assayed for cytokine expression. 
Uninfected cells were used as controls for basal cytokine expression against which 
infected cultures were compared. Very large deviations from baseline levels were 
observed in CM with all cytokines during HIV infection except for TNF and IFN-γ. 
MDMs had comparatively high basal levels of cytokines, particularly pro-
inflammatory cytokines in uninfected cultures, when compared to MDMs. Only 10 
out of 27 cytokines were significantly up-regulated. Virus-free co-cultures showed a 
suppression, rather than a cumulative effect in cytokine expression when compared to 
MDM alone, presenting a profile more closely resembling that of CM single cultures. 
Statistically significant deviations from uninfected control cultures, as determined by 
the t-test, are indicated by asterisks, where, *, **, *** indicate P values of less than 
0.05, 0.005 and 0.0005 respectively. Cytokine modulation was denoted as: ↑ More 
than 2.5-fold up-regulation; ↓ down-regulation; − no change or minimal up-
regulation, of less than 2.5-fold. 
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3.3 - CM apoptosis in the uninfected CM/HIV-infected MDM co-culture 
 system was inhibited by UCLA-1 or the simultaneous neutralization of  
IL-1β, IL-6 and TNF 
 
Extensive CM apoptosis was observed in infected MDM/uninfected CM co-cultures, 
effectively reducing cell viability to 43.7 ± 6.7 %, when compared to untreated 
controls (Figure 3). No change in cell viability was observed between infected and 
mock infected MDM cultures (Figure 3). Complete CM protection was achieved in 
the presence of UCLA1 (Figure 3) as well as by neutralizing IL-1β, IL-6 and TNF 
simultaneously (Figure 4). Treatment with TNF-R1 and neutralization of IL-1β and 
IL-6, conferred partial protection only (Figure 4). There was no statistical difference 
between mock infected and UCLA1-treated HIV-infected CM samples (95.8 % Vs 
97.2 % cell viability, P = 0.16). An equal effect to that observed with UCLA-1 
treatment, was observed with the simultaneous neutralization of IL-1β, IL-6 and TNF, 
resulting in complete CM protection (97.2 ± 1.6 % from treated Vs 41.8 ± 5.0 % for 
untreated cells, P = 0.001). This contrasted with TNF-R1-only treated, infected 
cultures where cell viability was maintained at 84.9 ± 3.2 % (P = 0.0012). A near 
identical degree of protection was conferred when cultures were treated with TNF-R1 
and IL-1β or TNF-R1 and IL-6 (81.8 ± 3.5 %, P = 0.003 for TNF-R1 + IL-1β Vs 85.7 
± 2.5 %, P = 0.003 for TNF-R1 + IL-6).  
The co-neutralization of IL-1β and IL-6 also improved cell survival from 40.0 ± 3.6 % 
to 73.2 ± 3.7 %, P = 0.0003, albeit not by as much as TNF-R1 treatment or in 
combination with any the other antibodies targeting IL-1β or IL-6 (Figure 4). This 
effect however, was not achieved by neutralizing each cytokine independently, since 
cell survival did not improve when compared to untreated controls (47.3 ± 5 % in 
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treated Vs 45.0 ± 4 % in untreated, P = 0.5 for IL-1β and; 42.9 ± 4.6 % in treated Vs 
49.0 ± 4.7 % in untreated, P = 0.2 for IL-6). Under no conditions did MDM viability 
decrease. 
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Figure 3: Cell viability during HIV-1CM9 infection. Cells were cultivated either as 
single cultures or co-cultures and mock infected or infected with 100 ng/ml, p24 of 
HIV-1CM9. Cellular ATP was then measured as a correlate of cell viability. Cells 
approached 100 % viability in all infected MDM and infected cond. MDM cultures. 
Statistically significant variations from mock-infected cultures was observed in all 
infected, untreated CM cultures. Only in infected, UCLA1-treated cond CM cultures 
was there a significant deviation from sham infected cultures. Statistically significant 
deviations from sham-infected cultures were determined using the t-test and denoted 
by asterisks, where, *, **, *** indicate P values of less than 0.05, 0.005 and 0.0005 
respectively.   
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Figure 4: Protection of CM from apoptosis with neutralizing antibodies directed 
against TNF, IL-1β and IL-6 in the HIV-infected MDM + uninfected CM co-culture 
model. Day 7 MDMs were infected with HIV for 24 h. Thereafter, an equal number of 
CM were added to the HIV-infected MDM, together with 100 nM of neutralizing 
antibody targeting either one or several cytokines simultaneously. After a further 24 h, 
CM were removed by trypsin digestion and cellular ATP levels were measured. The 
data was plotted as bar graphs, showing cell viability in the presence (treated) and 
absence (untreated) of neutralizing antibodies.  
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3.4 - The cytotoxic effects on CM during co-culture with HIV-infected  
MDM can be mimicked in healthy, uninfected CM with recombinant  
TNF, IL-1β and IL-6  
 
Neither IL-1β nor IL-6 had any detrimental effect on healthy, uninfected CM cultures 
at a maximum concentration of 10 ng/ml (Table 1). However, when used in 
combination with TNF, they caused a significant decrease in the IC50 from 650 ± 73 
pg/ml to 190 ± 35 pg/ml for TNF + IL-1β and 230 ± 14 pg/ml for TNF + IL-6 (P < 
0.0001 for all values). An even sharper decline was observed in healthy CM cultures 
treated with all 3 cytokines simultaneously, resulting in a decrease of the IC50 to 190 ± 
35 pg/ml (P < 0.0001). 
 
 
Table 1: Dose-dependent cytokine-induced cytotoxicity of CM. Cells were exposed 
to TNF, IL-1β and IL-6 alone or in combination at a maximum concentration of 10 
ng/ml. After 24 h of incubation, cellular ATP levels were measured as a correlate of 
cell viability. The IC50 was extrapolated from a linear curve relating cytokine 
concentration to cell viability.  
 
Cytokine IC50 (pg/ml)* Fold-decrease in EC50# P values
$
 
TNF 650 ± 73 N/A N/A 
IL-1β >10,000 - - 
IL-6 >10,000 - - 
TNF + IL-1β 190 ± 35 3.4 < 0.0001 
TNF +IL-6 230 ± 14 2.82 < 0.0001 
IL-1β + IL-6 >10,000 -  
TNF + IL-1β + IL-6 120 ± 46 5.4 < 0.0001 
*For each individual cytokine 
# Compared to TNF treatment alone 
$
 Measured against the IC50 of TNF 
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4.0 - Discussion 
 
This is the first study that analysed the differential expression of a panel of 27 
different cytokines in CM and MDM during HIV infection. A direct link between 
cytokine expression in infected MDM to CM pathogenesis was clearly established, as 
the data from the co-culture system reveals, shedding further light into one of the 
many mechanisms of the multifactorial nature of HIVCM (Barbaro, 2003b). In a 
similar study, adult rat cardiac myocytes presented abnormal contractile function 
when exposed to medium where alveolar macrophages from the same species had 
been activated with endotoxins (Balligand et al., 1993). The only measured anomalies 
were reduced CM contraction as well as increased NO levels, unlike the extensive 
apoptosis reported in our study. There are however, significant differences between 
the two studies. Firstly, we did not use conditioned media but co-cultures, which 
ensure a continuous and steady production of cytokines, which mimics in vivo 
scenario more closely. It also exposed the CMs to a different spectrum and 
concentration of cytokines than what would be observed with conditioned media, 
since it would be erroneous to assume that the cytokine profile as well as cytokine 
concentrations remains uniform over a 24 h period. Furthermore, our model allowed 
for a degree of direct contact between infected MDM and uninfected CM, an event 
that is highly cytolytic (Heinkelein, Sopper, and Jassoy, 1995). Another important 
difference was that we activated the MDM by HIV infection rather than endotoxins. 
The cytokine profile under these circumstances might be similar, but not identical. 
Nevertheless the study by Heinkelein and colleagues shows that in the presence of 
antigen, the response mounted by activated tissue macrophages can have deleterious 
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effects in contractile cardiac tissue, independently of direct contact between the 
activated MDM and CM.  
 
We have also shown that the restoration of cytokine expression to pre-infection levels 
with UCLA1, strongly correlated with a significant improvement in CM survival. The 
potent, cross-clade HIV neutralization properties of UCLA-1 have been well 
documented (Cohen et al., 2008; Dey et al., 2005; Khati et al., 2003). This aptamer 
works by binding to the CCR5-binding pocket of the viral surface envelope 
glycoprotein 120 (gp120). Binding of gp120 to the CCR5 cell surface chemokine 
receptor is a vital step in viral entry, which is inhibited by the UCLA1 aptamer.  
 
Although HIV did have a profound effect on the upregulation of most cytokines in all 
culture conditions, especially in CM, it did not seem to significantly impact on cell 
viability of either cell type. In fact, infected MDM have been observed to produce 
HIV-1 for weeks to months, with minimal cytotoxicity (Collman et al., 1989; Crowe, 
Mills, and McGrath, 1987). Furthermore, it has also been reported that HIV easily 
infects primary neonatal rat ventricular myocytes, but does not replicate (Twu et al., 
2002). There was a a significant decrease in CM viability only in infected MDM and 
uninfected-CM cultures (Figure 3). The only difference between these cultures and 
HIV-infected CM cultures was TNF expression as well as significantly increased 
levels of two key pro-inflammatory cytokines in cardiovascular disease, IL-1β and IL-
6 (Long, 2001; Wollert and Drexler, 2001). It was striking that only TNF increased 
above pre-infection levels in infected co-cultures and MDM, but not in infected CM, 
indicating a much more critical role in CM apoptosis than any other cytokine studies, 
including IL-1β and IL-6. Moreover, TNF is strongly associated with HIVCM 
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(Barbaro, 2005a). TNF was one of the first cytokines ever identified and is produced 
upon activation by the immune system, causing significant necrosis in tumors of a 
broad range of animal models and extensive cytotoxicity in many immortalized cell 
lines (Wajant, Pfizenmaier, and Scheurich, 2003). It is also well documented for its 
ability to significantly increase HIV-replication in HIV-infected cells of the 
macrophage lineage (Han et al., 1996; Kedzierska et al., 2003; Poli et al., 1990; 
Suresh and Wanchu, 2006), but implicated in entry inhibition in uninfected, TNF 
primed cells (Herbein, Montaner, and Gordon, 1996). Furthermore, its role in 
cardiomyocyte apoptosis, both in the clinical setting (Matsumori et al., 1994; Parrillo 
et al., 1985; Satoh et al., 1996) and in ex-vivo models (Finkel et al., 1992; Twu et al., 
2002; Yokoyama et al., 1993) has been recognized. The mechanism of action through 
which TNF exerts its cytotoxicity is by direct interaction with the TNF type I receptor. 
This cell-surface receptor is ubiquitously expressed and mediates most of the death-
related cellular effects of TNF (Wajant, Pfizenmaier, and Scheurich, 2003). It tightly 
regulates TNF activity by shedding it from the cell surface, thereby decreasing its 
receptor density resulting in decreased binding sites for its ligand. The resulting 
soluble receptor also sequesters TNF further reducing its cytotoxic effects (Garton, 
Gough, and Raines, 2006; Xanthoulea et al., 2004). The end result of TNF signalling 
is expression of inducible nitric oxide synthase (iNOS) through the activation of NF-
κB (Finkel et al., 1992; Givertz and Colucci, 1998; Starling, 2005). Thus, supra 
physiological levels of nitric oxide (NO), the product of iNOS, a highly cardiotoxic 
molecule, are synthesized resulting in cardiomyocyte apoptosis. Therefore modulation 
of TNF, TNF-R1 and/or its downstream effector iNOS, would be essential in 
minimizing CM apoptosis. IL-1β and IL-6 signalling also results in NO production. 
However, the pleiotropy of these three cytokines and functional redundancy of IL-1β 
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and IL-6 have made it difficult to study their exact mechanisms of action in CM 
apoptosis. Nonetheless, we have shown that simultaneous neutralization of IL-1β, IL-
6 and TNF protected close to 100 % of the CM from apoptosis, whereas neutralization 
of TNF alone or in combination with IL-1β or IL-6 only, only protected 84.9 ± 3.2 %, 
81.8 ± 3.5 % and 85.7 ± 2.5 % of the CM respectively. Interestingly, there was no 
difference in CM survival when TNF was neutralized alone or in combination with 
the other two cytokines. However, when both IL-1β and IL-6 where neutralized 
concomitantly, there was a level of cellular protection very close to that conferred by 
the neutralization of TNF alone. This data is further evidence of the functional 
redundancy of IL-1β and IL-6, in that in the absence of one the other will induce the 
desired signalling cascade, but the presence of either of them is essential to augment 
TNF death signalling, as observed by the simultaneous neutralization of all three 
cytokines. The key role of these three cytokines was further demonstrated when 
healthy CM where treated with them in a dose-dependent manner. Although we did 
not observe CM apoptosis in the presence of IL-1β and IL-6 alone or in combination, 
we did observe a decrease of over 5-fold in the IC50 of TNF when cells were exposed 
to all three cytokines simultaneously. A significant decrease in the IC50 was also 
observed when cells were co-treated with TNF and one of the two cytokines. This 
further cemented the argument of the indirect role played by IL-1β and IL-6 in TNF 
death signalling. Indeed, IL-1β and IL-6 are secreted by several cell types stimulated 
with TNF (Delves and Roitt, 2000), but their overall impact in CM survival remains 
debatable, even though very high levels of these cytokines have been closely linked to 
cardiac pathology (Long, 2001; Wollert and Drexler, 2001).  However, studies have 
focused on CM contractile dysfunction (which is reversible) in the presence of these 
cytokines or macrophage-activated medium rather than cell death (Balligand et al., 
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1993; Finkel et al., 1992; Kan et al., 2005; Kan, Xie, and Finkel, 2006). Therefore, 
such intimate relationship between IL-1β, IL-6 and TNF, especially the augmentation 
of TNF in death signalling by these cytokines has not been previously reported.  
Another intriguing aspect of the information gained with the cytokine multiplexing is 
whether minor, yet statistically significant changes in cytokine levels post infection 
are, in fact, physiologically relevant. A broad range of cytokines fall in this category 
(Figure 2), producing a wealth of data regarding the modulation of these cytokines 
during HIV infection. This data could be used as a framework to gain further insight 
into CM morbidity using end-point-measurements other than apoptosis, since some 
cytokines could be involved in cardiac dysfunction without measurable loss in 
contractile tissue. 
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HAART has been one of the greatest triumphs to date in the ongoing fight over the 
HIV pandemic. Although not a cure, it has significantly decreased AIDS-related 
morbidity as well as minimized the spread of the disease, both vertically and 
horizontally (UNAIDS, 2008). However, the therapeutic burden on the patient has 
greatly increased as have the adverse side effects arising from chronic, life-long 
HAART (Barbaro et al., 2003; Chen, Hoy, and Lewin, 2007). Drug holidays whereby 
the patient interrupts HAART for a few months, have shown mixed, but overall, 
discouraging results, whereby increased blood viraemia and drug resistance emerge 
significantly quicker than it otherwise would (SMART study, 2009). Drug resistance 
in fact, remains the major concern of antiretroviral therapy, which resulted in the need 
for the continuous development of novel drugs, exploiting both old and novel targets 
within the virus life cycle. An important pre-requisite for novel ARVs is decreased 
toxicity. This factor is, in fact, the major hindrance to drug development. The vast 
majority of promising leads during drug discovery fail the toxicity trials, a fact that 
also holds true for ARVs. Therefore, before any drug can be considered for further 
testing, it has to have an acceptable, in vitro toxicity profile. For this reason, and 
before any further work was carried out with the HIV-1 neutralizing aptamer UCLA1, 
a comprehensive in vitro toxicity testing was undertaken (Lopes de Campos et al., 
2009). It was encouraging to observe that B40 had no measurable effect on cell 
viability when compared to other ARVs and neither did it have an effect on 
monoamine oxidase CYP 450 3A4, amine oxidases MAO A and B and mitochondrial 
DNA synthesis. However, the observations made in this study are very limiting, since 
it encompassed the use of tissue-culture adapted cardiomyocytes in an in vitro system 
and the data may not have any correlation with in vivo events. In fact, the high levels 
of toxicity presented by PIs in this study do not directly correlate with clinical data. In 
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fact, PIs are better tolerated than any other class of ARVs and have a good safety 
profile (Walmsley, 2007). However, increasingly more frequent cardiovascular 
complications have been reported, particularly problems associated with cholesterol 
metabolism and decreased insulin sensitivity (Barbaro, 2006; Martinez, Larrousse, 
and Gatell, 2009). In the most severe cases, PI therapy has to be discontinued to allow 
for the resolution of these complications, since PIs interfere with several therapeutic 
agents used to treat cholesterol-associated cardiovascular complications (Hulten et al., 
2009). In light of this fact, although HIV-associated cardiomyopathy has been near 
abolished in the presence of HAART, PIs have re-introduced cardiovascular disease 
from a different perspective.  
 
HIVCM has drawn a comparatively lower degree of interest from the scientific 
community than the vast majority of other AIDS-associated diseases, due to the fact 
that it’s burden during has appeared to have decreased significantly with the 
introduction of HAART. Evidence of this rests on very limited number of peer-
reviewed articles published since the disease was first documented nearly two decades 
ago. One of the many possible explanations for this is that HIVCM is a condition that 
manifests itself very late during HIV-infection and long after the onset of AIDS, as a 
result of prolonged, chronic immunosuppression. The advent of ARVs, particularly of 
HAART, has largely eliminated this disease, but cardiac morbidity independently of 
HAART therapy still lingers, albeit at much lower and barely clinically relevant levels 
(Ntsekhe and Mayosi, 2008). However, this has only happened in the Western world, 
where all HIV-positive patients have ready access to HAART. In resource-limited 
countries, more specifically in sub-Saharan Africa, where over 70 % of HIV-infected 
patients live, significantly less HIV-positive patients have access to HAART 
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(Sendagire et al., 2009). One other facet of HIVCM that has possibly discouraged 
more intense research is its multifactorial nature from etiology to clinical outcome.  
Infection of cardiac tissue by opportunistic pathogens, especially TB and cardiotropic 
viruses has been recognized as the major cause of HIVCM (Barbaro, Fisher, and 
Lipshultz, 2001; Bowles et al., 1999; Currie et al., 1998; Hadigan et al., 2001; 
Herskowitz et al., 1994; Lewis, 2001; Twagirumukiza et al., 2007). However, a 
growing number of cases have been reported where no known pathogens could be 
identified in situ in patients presenting with early stages of the disease.                                                                                                                                                                                                
A direct role of HIV in cardiac pathology has been suspected in these cases, provoked 
either by direct infection of HIV or by cardiotoxic viral proteins, but evidence is still 
scant (Carr and Ory, 2006; Grody, Cheng, and Lewis, 1990; Lipshultz et al., 1990; 
Twu et al., 2002). Data collected in vitro has been more conclusive but, at times, 
controversial with most of the efforts focused on viral proteins, more specifically 
gp120 (Fiala et al., 2004; Finkel et al., 1992; Li et al., 2005; Raidel et al., 2002; Kan 
et al., 2000; Rebolledo et al., 1998; Roggero et al., 2001). Direct effects arising from 
the interaction between virions and cardiomyocytes has been poorly investigated, and 
research groups reporting on this issue have never pursued it as indicated by the 
absence of any follow up studies. A key question of HIV pathogenesis in 
cardiomyocytes was their ability to infect and replicate in these cells. I’ve shown that 
HIV does indeed infect CM, but viral replication is blocked after reverse transcription. 
This observation has been made in the past, but in neonatal rat ventricular myocytes 
(Twu et al., 2002). The question as to why the virus life cycle is interrupted following 
reverse transcription remains to be answered, but observations made in a different 
study using foetal human cardiomyocytes allows for some postulation (Rebolledo et 
al., 1998). In this study it was observed that HIV could in fact replicate relatively 
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efficiently in this early, embryonic cardiomyocytes. The CM employed in my study 
was an immortalized cell line obtained from mature cord-blood cell derived CM. 
Adult CM are terminally differentiated and this is one of the several reasons as to why 
CM are unable to complete their life cycle, even though this CM line is mitotically 
active. Embryonic CM, have some proliferative capability and are phenotypically 
distinct. Since there is no pro-viral DNA integration as observed in my study where a 
time-dependent decrease in pro-viral DNA was observed coupled with an inhibition in 
proviral DNA synthesis in the presence of AZT, a viral reverse transcriptase inhibitor, 
it was possible to identify the stage at which the viral life cycle was interrupted. 
Following proviral DNA synthesis, the proviral DNA is transported to the nucleus for 
integration, a process that is aided by viral and host factors (Campbell and Hope, 
2008; Gomez and Hope, 2005). It is likely that in adult cardiomyocytes, some of the 
proteins involved in the nuclear translocation process are absent, thereby arresting the 
viral life cycle at this stage. Future studies should focus on elucidating which host 
factors are responsible from stopping HIV from actively replicating in 
cardiomyocytes since these are some of the most metabolically active cells in the 
body. Usually what restrains productive infection is the entry step, but HIV 
successfully invaded these cells. Understanding the underlining cellular mechanisms 
stopping post-transcription/pre-integration events, which was were the life cycle of 
the virus was arrested, could provide novel targets for HIV therapy.  
 
I then looked into the relationship between cardiomyocyte infection and co-receptor 
utilization. HIV infection is almost exclusively receptor mediated, requiring an initial 
interaction between the viral surface envelope glycoprotein gp120 and the cell surface 
receptor CD4 (McClure, Marsh, and Weiss, 1988; Pauza and Price, 1988). This event 
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is followed by interaction with a second co-receptor, either the CCR5 or CXCR4 
(Jiang, 1997; Wu et al., 1996), although others have been identified but play minor 
roles during HIV infection in vivo (Cilliers et al., 2005; He et al., 1997). Co-receptor 
utilization defines virus tropism, which could be either R5, X4 or dual, R5X4. By 
making use of clinical isolates with known tropism (Cilliers et al., 2005) as well as 
inhibitors that blocked virus invasion by targeting either X4 or R5, I’ve shown that 
HIV-1 infection of this CM cell line was receptor independent. Receptor independent 
HIV infection has been reported in neuronal cells, believed to be mediated by 
macropinocytosis and lipid rafts (Liu et al., 2002), although the exact mechanism is 
yet to be fully elucidated. All clinical isolates with different tropisms successfully 
invaded CM, an observation made by the successful amplification of proviral DNA in 
CM following virus incubation. Furthermore, infection could not be blocked in the 
presence of either AMD3100 (CXCR4 inhibitor) and RANTES (CCR5 inhibitor). In 
PHA-treated, IL-2 stimulated PBMC control cells, all viruses were neutralized in a 
tropism-dependent manner.  
 
Further studies were conducted aimed at dissecting the downstream events following 
virus the interaction of HIV-1 with cardiomyocytes, even though the virus was unable 
to complete its life cycle. Extensive cell death was observed following three days of 
exposure of CM to HIV. CXCR4 and CCR5/CXCR4 utilizing viruses were, on 
average, three-fold more toxic than CCR5 tropic strains. Inhibition of cell death by 
AMD3100 and UCLA1 but not RANTES, indicated that the CXCR4 chemokine 
receptor may be the receptor that transduces the death signal. Earlier studies in MDM 
and more recent studies in neonatal rat ventricular myocytes have mapped this 
receptor as the death signaling receptor in the presence of soluble gp120 (Berndt et 
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al., 1998; Herbein et al., 1998; Yuan et al., 2008). Furthermore, inhibition of cell 
death by the highly selective caspase-9 inhibitor Z-LEHD-FMK, pointed to apoptosis 
as the death mechanism and the mitochondria or intrinsic pathway as the preferred 
pathway. Further evidence of this was the minimal protective effect against apoptosis 
by the selective caspase-8 inhibitor Z-IETD-FMK, since caspase-8 is the canonical 
caspase in the death-receptor or extrinsic apoptotic pathway (Wallach, Kang, and 
Kovalenko, 2008). The selective caspase-9 inhibitor also decreased the amount of 
Cytchrome c released from HIV-infected CM as well as nuclear DNA fragmentation 
in the same cells. Cytochrome c release into the cell cytosol is intimately associated 
with intrinsic apoptosis and, in fact, is required to activate the caspase-9 from its pro-
caspase precursor (Riedl and Salvesen, 2007). The caspase-8 inhibitor on the other 
hand, had virtually no protective effect. All this data argues for a mitochondria-
initiated pathway, triggered by the interaction between cell-free HIV-1 and the cell 
surface chemokine receptor CXCR4 as the key events in HIV-1 initiated CM 
apoptosis. 
 
Interestingly, a shift from caspase-9 to caspase-8 mediated apoptosis was observed 
when CM were co-cultured with HIV-infected MDM. In this scenario, neither the 
selective caspase-9 inhibitor Z-LEHD-FMK nor UCLA1 had a protective effect of 
CM viability. Protection was only achieved with the selective caspase-8 inhibitor Z-
IETD-FMK and the soluble TNF death receptor TNF-R1. Furthermore, there was no 
change in the apoptotic potential of HIV based on tropism, since both X4 and dual-
tropic viruses had a near identical effect on CM survival. This indicated a shift in the 
apoptotic pathway, from CXCR4-triggered, mitochondrial-mediated to Fas-
ligand/death receptor triggered, caspase-8 mediated. Multiplexing for 27 different 
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cytokines under these culture conditions revealed that TNF was only produced in 
HIV-infected MDM but not in HIV-infected CM. This was further indication that the 
change in the apoptotic pathway occurred as a result of a shift in the apoptotic stimuli.  
 
The evidence for the switch in apoptotic pathway was further strengthened when 
neutralizing antibodies against IL-1β and IL-6 were added to HIV-infected MDM, 
CM co-cultures, in addition to TNF-R1. I observed that single neutralization of IL-1β 
or IL-6 had no effect on cell survival, but when both were neutralized at the same 
time, the effect on cell survival was very similar to that conferred in the presence of 
TNF-R1 alone. This indicated that both IL-1β and IL-6 had an additive effect on the 
death signal generated by TNF, and either one of them was capable of triggering this 
effect, indicating a degree of functional redundancy of IL-1β and IL-6, although the 
protective effect brought about by the concomitant neutralization of all 3 cytokines 
was even greater than that obtained with TNF-R1 and either IL-1β or IL-6 
neutralization. This data further indicated that the up-regulation of these pro-
inflammatory cytokines were directly linked to CM apoptosis, rather than HIV itself. 
Moreover, when recombinant TNF was added to healthy CM cultures, a dose-
dependent decrease in cell viability was observed during the course of 24 h. It was 
further observed that when the pro-inflammatory cytokines IL-1β and IL-6 were 
added to the same culture medium there was a significant reduction in the EC50 of 
TNF, thereby augmenting its death-signal by between 2.82 and 5.4-fold. 
 
In the co-culture model of HIV-initiated cardiomyocyte apoptosis, UCLA1 had no 
protective effect. This was somewhat expected since UCLA acts directly on the virus, 
preventing infection. Once infection has established in MDM, the death signal shifts 
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from the virus to the up-regulation of TNF, IL-1 and IL-6, upon which UCLA1 has no 
effect. However, the role of UCLA1 in CM survival during HIV infection cannot be 
denied, even in the co-culture system, since if HIV is pre-incubated with UCLA1 
prior to infection of MDM, there is no infection, resulting in no loss of MDM. 
UCLA1 would also prevent infection of bystander cells by neutralizing infectious 
virions produced by infected cells, thereby containing the infection. However, this is 
also achieved by conventional ARVs in the clinical setting. What is unique to UCLA1 
is that, by binding to cell-free virus directly and interfering with gp120-CXCR4 
signaling, the mitochondrial initiated apoptotic pathway triggered by non-infectious 
virions is blocked. 
 
The evidence gathered from this body of work suggests that both viral and host 
factors are key contributors for HIVCM. It however points to a more direct role of 
HIV in cardiomyocyte pathogenesis than previously acknowledged. All research 
efforts and evidenced obtained pointed to viral proteins, more specifically gp120 to 
the almost complete exclusion of virions, as the viral mediators of apoptosis (Biard-
Piechaczyk et al., 2000; Fiala et al., 2004; Otis et al., 2008; Roggero et al., 2001; Twu 
et al., 2002; Yuan et al., 2008). Furthermore, the role of IL-1β and IL-6 in increasing 
CM sensitivity to TNF had yet to be reported. It has been widely described that they 
are key inflammatory cytokines and are involved in a wide array of cardiac 
inflammatory diseases (Long, 2001; Wollert and Drexler, 2001), but the manner in 
which they may bring about the loss of contractile cardiac tissue is still poorly 
understood. The observations made in this n vitro model of cardiomyocyte apoptosis 
during HIV infection may provide a framework for future therapeutic interventions 
targeting the host cytokines IL-1β and IL-6 concomitantly. The importance of 
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neutralizing both cytokines simultaneously for maximum therapeutic effects was 
evident in this model. However, this model remains a crude approximation of in vivo 
events. A mouse model needs to be established, using the parameters set in this study 
whereby IL-1β, IL-6 and TNF are administered to live mice and its effects not only in 
cardiomyocyte apoptosis but also in the heart as a whole, can be observed.  
 
This study shows once again the multifactorial nature of HIVCM, whereby viral, host 
and therapeutic factors are intimately involved in the progression to cardiac failure. 
However, HIV infection is the trigger and, ultimately, this is where our efforts must 
be focused.  The clinical use of UCLA1 is not yet feasible, but its efficacy and unique 
mode of action judging by the mounting body of evidence gathered over the last 6 
years, coupled with its toxicity profile, suggests that it may prove to be an effective 
antiretroviral. However, as discussed in the Introduction chapter of this dissertation, 
HIV neutralizing aptamers need to be made orally available, inexpensive and have a 
favourable pharmacokinetic profile. 
  
There is a general perception that HIVCM has been eradicated in first world countries 
with the introduction of HAART, which has decreased the interest of the medical and 
scientific community in further understanding the underlying mechanisms of this 
complex disease. This apparent neglect may have profound consequences in the near 
future as the HAART-treated population surpasses its first decade. There has been a 
recent surge in idiopathic cardiovascular complications in HIV positive patients, 
independently of HAART, even though viral loads are almost always maintained at 
levels below the threshold of detection. However, there are still basal levels of viral 
replication and an increase in blood viraemia is observed on a regular basis as escape 
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mutants. This issue is further compounded by increasing number of patients that are 
kept on a virologically failing regime for short-term immunological or virological 
benefit (Cozzi-Lepri et al., 2007; Deeks et al., 2001). Although there are no clinical 
manifestations of disease, both from a serological as well as physiological 
perspective, the presence of virions in the blood may eventually lead to cardiac 
complications, if there is any correlate between the in vitro data gathered during the 
course of this study and clinical cardiac morbidity.  In future, we are very likely to 
observe an even greater increase in idiopathic cardiovascular morbidity which may be 
directly related to chronic HIV infection.  
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